0001562762-22-000139 | 10-K | XBRL Viewer

Print Document View Excel Document

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (137,175)	$ (39,957)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,102	717
Amortization of debt issuance costs	261	108
Change in fair value of Series A preferred stock	30,412	1,014
Stock-based compensation expense	280	0
Non-cash interest expense	0	582
Change in fair value of convertible notes	2,667	5,761
Change in fair value of warrant liability	214	41
Change in fair value of simple agreements for future equity	8,365	615
Changes in operating assets and liabilities:
Accounts receivable	26	(26)
Amounts due to related parties	(31)	(1,743)
Prepaid expenses and other current assets	(4,704)	(3,488)
Deferred offering costs	2,254	(2,254)
Accounts payable	2,174	(267)
Amounts due to related parties	11,402	4,608
Accrued expenses and other current liabilities	1,775	285
Other liabilities	(12)	94
Net cash used in operating activities	(80,990)	(33,910)
Cash flows from investing activities:
Purchase of property and equipment	(1,318)	(1,477)
Net cash used in investing activities	(1,318)	(1,477)
Cash flows from financing activities:
Proceeds from issuance of convertible notes payable with related parties	2,000	12,040
Repayment of convertible notes	(2,000)	(5,500)
Repayments Of Related Party Debt	414	202
Repayments Of Medium Term Notes	100	0
Payment of debt issuance costs for related party convertible notes	(300)	0
Proceeds from Paycheck Protection Program	257	0
Proceeds from exercise of stock options	79	170
Net cash provided by financing activities	66,109	196,167
Increase in cash, cash equivalents, and restricted cash	30,722	113,859
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance	31,198	476
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	145,057	31,198
Supplemental Disclosure
Cash paid for interest	581	425
Noncash Financing Activities
Acquisition of airplane through issuance of note payable	0	11,500
Fair value of warrants issued in connection with preferred stock issuance	0	573
Reitrement Of Treasury Shares	0	23
Fair Value of Restricted Stock, Vested	0	1
Series Seed-1 Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	4,467	0
Series Seed-2 Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	10,955	0
Series B Preferred Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	0	122,791
Series A-1 Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	4,999	0
Series A-2 Stock [Member]
Payment for convertible preferred stock issuance costs	(41)	0
Class A Common Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	0	71,077
Simple Agreement for Future Equity [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	39,355	2,900
Conversion Of Stock Amount Issued 1	35,600	0
Series A and Series B to Class A Common Stock [Member]
Conversion Of Stock Amount Issued 1	251,230	0
Series Seed, Series Seed-1, Series Seed-2, Series A-1 and Series A-2 for Series A [Member]
Conversion Of Stock Amount Issued 1	62,475	0
Convertible Notes Payable to Series A Preferred [Member]
Conversion Of Stock Amount Issued 1	27,545	0
Notes Payble to Series A Preferred [Member]
Conversion Of Stock Amount Issued 1	2,205	0
Warrant to Series A Preferred [Member]
Conversion Of Stock Amount Issued 1	614	0
Warrant to Class A Common Stock [Member]
Conversion Of Stock Amount Issued 1	177	0
SAFE to Series A2 Preferred [Member]
Conversion Of Stock Amount Issued 1	0	15,275
SAFE to Seed2 Preferred [Member]
Conversion Of Stock Amount Issued 1	0	360
Warrant to Series A1 Preferred [Member]
Conversion Of Stock Amount Issued 1	$ 0	$ 214

Common Stock (Narrative) (Details) - $ / shares	12 Months Ended
Common Stock (Narrative) (Details) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Issuance of stock, shares	32,505,306
Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	6,000,000
Share Price	$ 13.00
Common stock, shares authorized	1,000,000,000	129,916,912
Common stock, par value	$ 0.0001	$ 0.0001
Class A Common Stock [Member] \| Chief Executive Officer [Member]
Class Of Stock [Line Items]
Shares converted	2,874,983
Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	100,000,000	10,999,149
Common stock, par value	$ 0.0001	$ 0.0001
Common Stock [Member] \| Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	6,537,711
Amended And Restated Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	1,100,000,000
Common stock, par value	$ 0.0001
Amended And Restated Common Stock [Member] \| Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	1,000,000,000
Amended And Restated Common Stock [Member] \| Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	100,000,000
UNS [Member] \| Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	60,360,523
Shares converted	0.2191
UNS [Member] \| Common Class B [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	10,999,149
Shares converted	3.4233

Income Taxes (Schedule of Unrecognied Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Beginning balance, January 1	$ 652	$ 646
Gross increase, tax positions in current period	0	6
Ending balance, December 31	$ 652	$ 652

Consolidated Statements of Equity (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Series Seed-1 Stock [Member]
Issuance of stock, issuance costs		$ 18
Series Seed-2 Stock [Member]
Issuance of stock, issuance costs		45
Series A-1 Stock [Member]
Issuance of stock, issuance costs		585
Series A-2 Stock [Member]
Issuance of stock, issuance costs		41
Series B Preferred Stock [Member]
Issuance of stock, issuance costs		$ 133
Common Stock [Member] \| Class A Common Stock [Member]
Issuance of stock, issuance costs	$ 13,913

Commitments and Contingencies (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($) ft² shares	Dec. 31, 2020 USD ($)
Commitments And Contingencies [Line Items]
Security deposit	$ 0.1
Rent expense	$ 0.1	$ 0.1
Shares issued \| shares	32,505,306
Lease in square feet \| ft²	5,012
Lease obligation	$ 0.2
Project Grant	0.8
Grant, Accrued Liability, Current	0.0
Grant, Accrued Liability, NonCurrent	0.0
Grant, Decrease In Research And Development	0.1
Amortization Of Intangible Assets	0.1
Increase Decrease In Intangible Assets Current	13.3
Contract Research Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments	1.6
Contract Manufacturing Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments	$ 2.5

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	19. Subsequent Events The Company has evaluated subsequent events through March 24, 2022 and has concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements.

Prepaid Expenses and Other Current Assets (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	$ 10	$ 4,379
Related Party [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	1,000
Vaccine Development [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	$ 2,500

Equity Incentive Plan (Narrative) (Details - USD ($)	12 Months Ended
Equity Incentive Plan (Narrative) (Details - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	21,387,909	9,276,399	7,610,289
Options exercisable	13,439,566
Total stock-based compensation expense	$ 1,014,000	$ 30,412,000
Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant		1,897,049
Options outstanding		9,276,399
Minimum [Member] \| Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	1 year
Employee and Non-Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
2021 Stock Option and Grant Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost	$ 26,800,000
Recognized over a weighted average period	3 years 3 months 18 days
2021 Stock Option and Grant Plan [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant	7,209,538
Intrincic value of options exercised	$ 100,000	$ 100,000
Weighted-average grant-date fair value per share of options granted	$ 4.21	$ 0.50
Total fair value of options vested	$ 24,500,000	$ 800,000
2021 Stock Option and Grant Plan [Member] \| First Anniversary [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total fair value of options vested	5,439,700	6,799,625
2021 Stock Option and Grant Plan [Member] \| First Anniversary [Member] \| Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total fair value of options vested	$ 100,000	$ 100,000
2021 Stock Option and Grant Plan [Member] \| Board of Directors [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options exercisable	815,955
Intrincic value of options exercised	$ 300,000
2021 Stock Option and Grant Plan [Member] \| Class A Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan	21,593,830
2021 Stock Option and Grant Plan [Member] \| Class A Common Stock [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan	8,700,000
Number of shares available for grant	7,209,538
Options outstanding	15,025,454
Options exercisable	8,652,630
2021 Stock Option and Grant Plan [Member] \| Class A Common Stock [Member] \| Employee and Non-Employees [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options exercisable	6,799,625
2021 Stock Option and Grant Plan [Member] \| Common Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant	6,362,455
2021 Stock Option and Grant Plan [Member] \| Common Class B [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	6,362,455
Options exercisable	4,786,936
2021 Stock Option and Grant Plan [Member] \| Common Class B [Member] \| Employee and Non-Employees [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	5,983,670
Total fair value of options vested	$ 23,800,000

Benefit Plans (Narrative) (Details) - Foreign Plan [Member] - Personal Retirement Savings Account [Member] $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Defined Contribution Plan Disclosure [Line Items]
Company contribution percent	5.00%
Company contributions	$ 0.1

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2021
Fair Value Measurements [Abstract]
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis	December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market account $ — $ — $ — $ — Total assets $ — $ — $ — $ — Liabilities: Convertible notes payable $ — $ — $ 10,356 $ 10,356 Convertible notes with related parties — — 14,324 14,324 SAFEs — — 24,335 24,335 Warrant liability — — 400 400 Total liabilities $ — $ — $ 49,415 $ 49,415 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market account $ 139,794 $ — $ — $ 139,794 Total assets $ 139,794 $ — $ — $ 139,794
Schedule of Carrying Amounts and Estimated Fair Values of Financial Instruments	Convertible Notes Balance at December 31, 2019 $ 12,121 Issuance of convertible notes 12,040 Repayments (5,500) Change in fair value 5,761 Issuance costs (300) Amortization of issuance costs 83 Accrued interest 475 Balance at December 31, 2020 24,680 Issuance of convertible notes 2,000 Repayments (2,000) Change in fair value 2,667 Amortization of issuance costs 217 Accrued interest 168 Interest paid (187) Conversion to Series A preferred stock (27,545)
Schedule of Fair Value Measured on a Nonrecurring Basis	Convertible Notes Balance at December 31, 2019 $ 12,121 Issuance of convertible notes 12,040 Repayments (5,500) Change in fair value 5,761 Issuance costs (300) Amortization of issuance costs 83 Accrued interest 475 Balance at December 31, 2020 24,680 Issuance of convertible notes 2,000 Repayments (2,000) Change in fair value 2,667 Amortization of issuance costs 217 Accrued interest 168 Interest paid (187) Conversion to Series A preferred stock (27,545)
Schedule of Activity in Level 3	SAFE Liability Balance at December 31, 2019 $ — Issuance of SAFEs 39,355 Change in fair value 615 Conversion to Series Seed-2 convertible preferred stock (360) Conversion to Series A-2 convertible preferred stock (15,275) Balance at December 31, 2020 24,335 Change in fair value 8,365 Issuance of SAFEs 2,900 Conversion to Series A preferred stock (35,600) Warrant Liability Balance at December 31, 2019 $ — Issuance of Series A-1 preferred warrants 573 Exercise of warrants (214) Change in fair value 41 Balance at December 31, 2020 400 Change in fair value 214 Conversion to warrants for shares of Series A preferred stock (614)

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Dec. 31, 2021
Related Party Transactions [Abstract]
Schedule of Related Party Operating Activity	December 31, 2021 2020 Consolidated balance sheet Assets Prepaid expenses and other current assets $ 3,517 $ 2,867 Property and equipment, net 337 725 Accrued expenses — 285 Amounts due from related parties 393 361 Liabilities Amounts due to related parties 19,407 8,004 Years Ended December 31, 2021 2020 Consolidated statement of operations Revenue $ — $ 162 Cost of revenue — 52 Operating expenses Research and development Services provided by related parties 41,430 17,987 Taiwan CDC grant reimbursement from related party (7,199) (2,948) General and administrative Services provided by related parties 1,173 3,147

Convertible Preferred Stock (Schedule of Preferred Stock) (Details) - shares	Dec. 31, 2021	Nov. 14, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Preferred stock, share outstanding		77,588,669
Common Stock Issuable Upon Conversion	49,864,120
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding		62,223,095	0
Common Stock Issuable Upon Conversion	39,989,083
Series B Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding	0		0
Series B Preferred Stock Issued March 2021 [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding		9,923,711
Common Stock Issuable Upon Conversion	6,377,699
Series B Preferred Stock Issued June 2021 [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding		5,441,863
Common Stock Issuable Upon Conversion	3,497,338

Income Taxes (Reconciliation of Income Tax Percent) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
U.S. federal statutory income tax rate	21.00%	21.00%
State and local taxes, net of federal benefits	0.50%	0.29%
Foreign rate differential	(0.74%)	(4.06%)
Uncertain tax positions	0.00%	0.00%
Other	(1.90%)	(0.36%)
Change in valuation allowance	(15.21%)	(16.87%)
Effective income tax rate	0.00%	0.00%

Benefit Plans	12 Months Ended
Benefit Plans	Dec. 31, 2021
Benefit Plans [Abstract]
Benefit Plans	17. Benefit Plans In March 2018, the Company established a defined contribution savings plan under Section 401(k) of the Code. This plan covers substantially all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company does not make matching contributions to the Plan. The Company offers its Ireland-based employees a Personal Retirement Savings Account (“PRSA”) that allows participants to defer a portion of their annual compensation. The Company provides contributions equal to 5 % of each participant’s annual salary. During both of the years ended December 31, 2021 and 2020, the Company contributed less than $ 0.1 million to PRSA accounts.

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2021
Income Taxes [Abstract]
Schedule of Loss Before Income Taxes	Years Ended December 31, Losses before taxes 2021 2020 Domestic entities $ (128,538) $ (31,053) Entities outside the U.S. (8,636) (8,904) (137,175) $ (39,957)
Schedule of Income Tax Expense	Years Ended December 31, 2021 2020 Current: Federal $ — $ — State and local — — Foreign — — Total current tax expense — — Deferred tax (benefit): Federal — — State and local — — Foreign — — Total deferred tax (benefit) — —
Reconciliation of Income Tax Percent	Years Ended December 31, 2021 2020 Income taxes at statutory rate 21.00 % 21.00 % State income taxes, net of federal benefit 0.50 % 0.29 % Stock compensation (3.65) % 0.00 % Foreign rate differential (0.74) % (4.06) % Uncertain tax positions 0.00 % 0.00 % Other (1.90) % (0.36) % Change in valuation allowance (15.21) % (16.87) % Provision for income taxes 0.00 % 0.00 %
Schedule of Deferred Tax Assets	As of December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 32,405 $ 12,373 Compensation accruals 1,735 377 Other 27 627 Total deferred tax assets 34,167 13,377 Less: valuation allowance (34,106) (13,247) Net deferred tax assets $ 61 $ 130 Deferred tax liabilities: Depreciation $ (61) $ (130) Net deferred tax liabilities (61) (130) Net deferred income taxes $ — $ —
Schedule of Unrecognized Tax Benefits	Years Ended December 31, 2021 2020 Uncertain tax position liability at the beginning of the year $ 652 $ 646 Increases (decreases) related to tax positions taken during current period — 6 Uncertain tax position liability at the end of the year $ 652 $ 652

Notes payable (Tables)	12 Months Ended
Notes payable (Tables)	Dec. 31, 2021
Notes payable with related parties [Abstract]
Activity of the notes payable with related parties	2018 Related Notes and 2019 Executive Note Related Party Principal Accrued Interest Balance December 31, 2019 $ 2,100 $ 88 $ 2,188 Additions — 106 106 December 31, 2020 2,100 194 2,294 Accrued interest — 19 19 Repayment (100) — (100) Interest paid — (8) (8) Conversion (2,000) (205) (2,205) December 31, 2021 $ — $ — $ —
Schedule of Maturities of Notes Payable	Amount 2022 $ 429 2023 444 2024 458 2025 9,552 $ 10,883

Net Loss Per Share (Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	68,094,756	23,315,929
Series Seed Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	7,831,528	0
Series Seed-1 Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	22,876,457	0
Series Seed-2 Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	14,615,399	0
Series A-1 Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	1,871,511	0
Series A-2 Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	6,307,690	0
Unvested restricted stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	23,970	0
Options issued and outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	14,434,095	21,387,909
Warrants issued and outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	134,106	1,928,020

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2021
Fair Value Measurements [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company's money market accounts are shown at fair value based on unadjusted quoted market prices in active markets for identical assets. The value for the Convertible Notes, SAFE and warrant liability balances as of December 31, 2020 are based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. In accordance with the Contribution and Exchange Agreement, on March 2, 2021 the Convertible Notes, SAFEs and warrants were all converted into Series A preferred stock. The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands): During the years ended December 31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3. Convertible Notes During the years ended December 31, 2021 and 2020, the Company issued Convertible Notes. In accordance with ASC 480, a portion of the Convertible Notes were required to be measured and accounted for at fair value at each reporting date. The Company determined the Convertible Notes requiring a measurement to fair value represent a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs. Convertible Notes requiring a measurement to fair value are as follows (in thousands): The fair value of the Convertible Notes was estimated using a straight debt and conversion feature valuation model consisting of probability assumptions on multiple conversion scenarios, discount rates and interest rates. In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the Convertible Notes were converted into Series A preferred stock. Simple Agreement for Future Equity—SAFE During the years ended December 31, 2021 and 2020, the Company executed SAFE arrangements. The fair value of the SAFEs on the date of issuance was determined to equal the proceeds received by the Company. The value of the SAFEs on the dates of conversion into preferred stock was determined to be equal to the fair value of the preferred stock issued, or $ 35.6 million during the year ended December 31, 2021 and $ 15.6 million during the year ended December 31, 2020. The following table sets forth a summary of the activities of the SAFE arrangements, which represents a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs (in thousands): In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the SAFEs were converted into Series A preferred stock. Warrants to Purchase Series A-1 Convertible Preferred Stock & Common Stock In connection with the 2020 Series A-1 convertible preferred stock (“Series A-1 preferred”) financing transactions, the Company issued fully vested warrants to purchase 205,970 shares of Series A-1 preferred. The warrants were issued to advisors as consideration for assistance with the sale and issuance of the Series A-1 preferred. The warrants were determined to represent issuance costs and were recorded as a reduction in the proceeds received from the sale. The warrants were issued to advisors of the company and represented non-variable contingently redeemable instruments. As such, the warrants were accounted for as liabilities and adjusted to fair value at each reporting period. The warrants are exercisable on the date of issuance and have an exercise price of $ 0.003 per share and a contractual term of ten years. In December 2020, warrants were exercised for 71,862 shares of Series A-1 at $ 0.003 per share, resulting in cash proceeds of less than $ 1,000 . As of December 31, 2020, warrants to purchase 134,106 shares of Series A-1 preferred were outstanding. The Company continued to re-measure the fair value of the liability associated with the warrant to purchase shares of Series A-1 preferred at the end of each reporting period until the Reorganization, when the warrant converted into Series A preferred stock and subsequently, in connection with the IPO, converted into Class A common stock. The following table sets forth a summary of the activity of the warrant liability which represented a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs (in thousands): December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market account $ — $ — $ — $ — Total assets $ — $ — $ — $ — Liabilities: Convertible notes payable $ — $ — $ 10,356 $ 10,356 Convertible notes with related parties — — 14,324 14,324 SAFEs — — 24,335 24,335 Warrant liability — — 400 400 Total liabilities $ — $ — $ 49,415 $ 49,415 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market account $ 139,794 $ — $ — $ 139,794 Total assets $ 139,794 $ — $ — $ 139,794 Convertible Notes Balance at December 31, 2019 $ 12,121 Issuance of convertible notes 12,040 Repayments (5,500) Change in fair value 5,761 Issuance costs (300) Amortization of issuance costs 83 Accrued interest 475 Balance at December 31, 2020 24,680 Issuance of convertible notes 2,000 Repayments (2,000) Change in fair value 2,667 Amortization of issuance costs 217 Accrued interest 168 Interest paid (187) Conversion to Series A preferred stock (27,545) SAFE Liability Balance at December 31, 2019 $ — Issuance of SAFEs 39,355 Change in fair value 615 Conversion to Series Seed-2 convertible preferred stock (360) Conversion to Series A-2 convertible preferred stock (15,275) Balance at December 31, 2020 24,335 Change in fair value 8,365 Issuance of SAFEs 2,900 Conversion to Series A preferred stock (35,600) Warrant Liability Balance at December 31, 2019 $ — Issuance of Series A-1 preferred warrants 573 Exercise of warrants (214) Change in fair value 41 Balance at December 31, 2020 400 Change in fair value 214 Conversion to warrants for shares of Series A preferred stock (614)

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of Significant Accounting Policies (Summary of Restatement-Statement of Stockholders' Deficit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Issuance of common stock upon exercise of stock options	$ 170	$ 79
Net loss	(137,175)	(39,957)
Stockholders' deficit	$ 128,619	$ (87,375)	$ (48,512)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Fair Value Measurements (Schedule of Activity in Level 3, Convertible Notes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Repayment of convertible notes	$ 2,000	$ 5,500
Payments Of Debt Issuance Costs	300	0
Convertible Debt [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	24,680	12,121
Proceeds from issuance of convertible notes payable	2,000	12,040
Repayment of convertible notes	2,000	5,500
Debt, Change In Fair Value	2,667	5,761
Payments Of Debt Issuance Costs	217	300
Amortization Of Financing Costs And Discounts	168	83
Interest On Convertible Debt Net Of Tax	187	475
Debt, Convesion Of Debt Fair Value	$ (27,545)
Balance		$ 24,680

Summary of Significant Accounting Policies (Summary of Restatement-Statement of Operations) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Revenue	$ 66	$ 557
Cost of revenue	1,937	52
Gross (loss) profit	(1,871)	505
Research and development	71,379	20,570
General and administrative	51,825	12,217
Total operating expenses	123,204	32,787
Loss from operations	(125,075)	(32,282)
Interest expense, net	840	1,182
Change in fair value of convertible notes	2,667	5,761
Loss on foreign currency translation, net	(23)	(77)
Other (income) expense	12,100	7,675
Net loss	$ (137,175)	$ (39,957)
Net loss per share, basic and diluted	$ (1.79)	$ (0.61)

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Series Seed Stock [Member]	Series Seed-1 Stock [Member]	Series Seed-2 Stock [Member]	Series A-1 Stock [Member]	Series A-2 Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Class A Common Stock [Member]	Class B Common Stock [Member]	Common Stock [Member]	Common Stock [Member] Class A Common Stock [Member]	Common Stock [Member] Class B Common Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member] Conversion To Class A Common Stock [Member]	Preferred Stock [Member] Series Seed Stock [Member]	Preferred Stock [Member] Series Seed-1 Stock [Member]	Preferred Stock [Member] Series Seed-2 Stock [Member]	Preferred Stock [Member] Series A-1 Stock [Member]	Preferred Stock [Member] Series A-2 Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] SAFEs [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Warrants [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Conversion To Class A Common Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Convertible Debt [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Notes Payable, Related Parties [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member] Conversion To Class A Common Stock [Member]	Treasury Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2019	$ (48,512)										$ 270	$ 0		$ 26,819		$ 10,383	$ 16,436	$ 0	$ 0	$ 0									$ (23)	$ 3,590	$ (52,349)
Beginning balance, common shares at Dec. 31, 2019											37,953,692	0	0
Beginning balance, preferred shares at Dec. 31, 2019																7,831,528	8,017,771	0	0	0
Beginning balance, treasury shares at Dec. 31, 2019																													3,169,093
Issuance of common stock upon exercise of stock options, shares	283,290										283,290
Issuance of common stock upon exercise of stock options	$ 79										$ 1																			78
Issuance of stock, shares																	14,858,686	14,152,237	1,799,649
Issuance of stock											$ 33,001,408						$ 4,467	$ 10,955	$ 4,426
Conversion of stock, shares																		463,162		6,307,690
Conversion of stock																		$ 360		$ 15,234
Exercise of warrants, shares																			71,862
Exercise of warrants																			$ 214
Vesting of restricted stock, shares											121,282
Vesting of restricted stock	1										$ 1
Stock-based compensation expense	1,014																													1,014
Reclassification of common stock to Class A, shares											(60,360,523)	60,360,523
Reclassification of common stock to Class A											$ (272)	$ 272
Reclassification of common stock to Class B, shares											(10,999,149)		10,999,149
Net loss	(39,957)																														(39,957)
Ending balance at Dec. 31, 2020	$ (87,375)										$ 0	$ 272		62,475		$ 10,383	$ 20,903	$ 11,315	$ 4,640	$ 15,234	$ 0						$ 0		$ (23)	4,682	(92,306)
Ending balance, common shares at Dec. 31, 2020									60,360,523	10,999,149	(10,999,149)	60,360,523	10,999,149
Ending balance, preferred shares at Dec. 31, 2020		10,452	22,876,457	14,615,399	1,871,511	6,307,690	0	0								7,831,528	22,876,457	14,615,399	1,871,511	6,307,690	0						0
Ending balance, treasury shares at Dec. 31, 2020									3,169,093																				3,169,093
Issuance of common stock upon exercise of stock options, shares	186,204											485,836
Issuance of common stock upon exercise of stock options	$ 170																													170
Issuance of stock, shares	32,505,306								6,000,000			6,537,711															15,365,574
Issuance of stock	$ 103											$ 1															$ 122,791			103
Exhange of preferred stock, shares																(7,831,528)	(22,876,457)	(14,615,399)	(1,871,511)	(6,307,690)	53,502,585
Exchange of preferred stock																$ (10,383)	$ (20,903)	$ (11,315)	$ (4,640)	$ (15,234)	$ 62,475
Conversion of stock, shares																						4,539,060	134,106	(62,223,095)	3,624,114	423,230		(15,365,574)
Conversion of stock															$ (251,230)							$ 35,600	$ 614	$ (128,439)	$ 27,545	$ 2,205		$ (122,791)
Exercise of warrants, shares												112,373
Exercise of warrants	177																													177
Vesting of restricted stock, shares												15,405
Retirement of treasury stock in merger, shares												(3,169,093)																	3,169,093
Retirement of treasury stock in merger																													$ 23	(23)
Stock-based compensation expense	30,412																													30,412
Reclassification of common stock to Class A, shares												49,864,120
Reclassification of common stock to Class A	251,230											$ 5																		251,225
Reclassification of common stock to Class B, shares												(2,874,983)	2,874,983
Net loss	(137,175)																														(137,175)
Ending balance at Dec. 31, 2021	$ 128,619											$ 278		$ 0		$ 0	$ 0	$ 0	$ 0	$ 0	$ 0						$ 0		$ 0	$ 357,822	$ (229,481)
Ending balance, common shares at Dec. 31, 2021									111,518,094	13,874,132		111,518,094	13,874,132
Ending balance, preferred shares at Dec. 31, 2021		0	0	0	0	0		0								0	0	0	0	0	0						0
Ending balance, treasury shares at Dec. 31, 2021									0																				0

Convertible Notes Payable (Tables)	12 Months Ended
Convertible Notes Payable (Tables)	Dec. 31, 2021
Notes Payable [Abstract]
Convertible Notes	Convertible Notes Principal Amount Payable Change in Fair Value Accrued Interest Issuance Conversion to Standard Related Party Standard Related Party Standard Related Party Costs Series A Balance December 31, 2019 $ 11,170 $ 510 $ 33 $ 26 $ 378 $ 4 $ — $ — $ 12,121 Additions 2,040 10,000 1,884 3,822 560 179 (300) — 18,185 Settlements (5,500) — 55 — (264) — — — (5,709) Amortization — — — — — — 83 — 83 December 31, 2020 7,710 10,510 1,972 3,848 674 183 (217) — 24,680 Additions — 2,000 812 1,855 58 110 — — 4,835 Settlements (2,000) — — — (187) — — — (2,187) Amortization — — — — — — 217 — 217 Conversion of Convertible Notes to Series A preferred stock (5,710) (12,510) (2,784) (5,703) (545) (293) — (27,545) (27,545) December 31, 2021 $ — $ — $ — $ — $ — $ — $ — $ (27,545) $ —

Other Long-Term Liabilities (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Accrued Payroll Taxes Current And Noncurrent	$ 0.2	$ 0.2
Income Tax Examination Penalties And Interest Accrued	$ 0.2

Summary of Significant Accounting Policies (Policy)	12 Months Ended
Summary of Significant Accounting Policies (Policy)	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation
Foreign currency translation	Foreign currency translation The Company’s consolidated financial statements are prepared in U.S. dollars. Its foreign subsidiaries use the U.S. dollar as their functional currency and maintain their records in the local currency. Nonmonetary assets and liabilities are re-measured at historical rates and monetary assets and liabilities are re-measured at exchange rates in effect at the end of the reporting period. Income statement accounts are re-measured at average exchange rates for the reporting period. The resulting gains or losses are included in foreign currency (losses) gains in the consolidated statements of operations.
Segment information	Segment information Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company has determined that it operates as a single operating segment and has one reportable segment.
Use of estimates	Use of estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates contained within these consolidated financial statements include, but are not limited to, the estimated fair value of the Company’s common stock and convertible notes payable, simple agreements for future equity, warrant liabilities, stock-based compensation, income tax valuation allowance and the accruals of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in facts and circumstances. Actual results may differ materially from those estimates or assumptions.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents, including balances held in the Company’s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time may exceed the U.S. federally insured limits. The objectives of the Company’s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company’s cash flow requirements, and to attain a market rate of return.
Restricted cash	Restricted cash December 31, 2021 2020 Cash and cash equivalents $ 144,885 $ 31,143 Restricted cash 172 55 Total cash, cash equivalents and restricted cash $ 145,057 $ 31,198
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company is dependent on contract manufacturers, several of whom are considered to be related parties, for manufacturing, quality control, testing, validation and supply services, including production, including production and shipment of its enzyme-linked immunosorbent assay (“ELISA”) tests, and for research and development and clinical activities. The Company’s future revenue as well as research and development programs could be adversely affected by a significant supply interruption by one or more of its contract manufacturers.
Accounts receivable	Accounts receivable
Property and equipment	Property and equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the assets. The estimated useful life of property and equipment is as follows: Estimated Useful Life Airplane 15 years Facilities 15 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in gain or loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.
Impairment of long-lived assets	Impairment of long-lived assets Long-lived assets, comprised of property and equipment, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses or disposals on long-lived assets.
Deferred offering costs	Deferred offering costs
Fair value measurements	Fair value measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets that are identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
Convertible notes payable	Convertible notes payable The Company issued convertible notes payable at various times from 2014 to 2021. The Company accounts for the convertible notes payable at fair value in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”). The notes payable with related parties are accounted for as straight debt under ASC 470, Debt (“ASC 470”). The Company has elected to separate interest expense from the full change in fair value of the convertible notes. Debt issuance costs incurred by the Company are amortized to interest expense over the term of the convertible notes using the effective interest method in the accompanying consolidated statements of operations.
Debt issuance costs	Debt issuance costs The Company records debt issuance costs as a reduction to the carrying value of the debt. The debt discounts are amortized over the term of the debt using the effective interest method and recognized as interest expense in the accompanying consolidated statement of operations.
Simple Agreement for Future Equity - SAFE	Simple Agreement for Future Equity—SAFE The Company accounts for SAFEs at fair value in accordance with ASC 480. The SAFEs are subject to revaluation at the end of each reporting period, with changes in fair value recognized in the accompanying consolidated statements of operations. On March 2, 2021, each SAFE that was outstanding was converted into shares of the Company’s Series A preferred stock (see Note 11).
Classification of convertible preferred stock	Classification of convertible preferred stock The Company records all convertible preferred stock at its original issuance price, less direct and incremental issuance costs, as stipulated by its terms. The Company’s convertible preferred stock is classified outside of stockholders’ deficit because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company.
Revenue recognition	Revenue recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts With Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled to in exchange for those goods or services. The Company applies ASC 606 to contracts with customers only when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by evaluating whether each promised good or service is distinct. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services, the intended benefit of the contract and whether each good or service is separately identifiable from the other aspects of the contractual relationship. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the most likely amount method and applies the constraint on variable consideration, which requires the amount included in the transaction price to be constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and, if over time, recognition is based on the use of an output or input method. In the Company’s sole revenue contract, the performance obligation was satisfied at the point in time the data and related samples were made available for the customer’s review. For its sales of ELISA tests, the Company recognizes revenue once control is transferred upon delivery to the customer.
Taiwan Centers for Disease Control Grant	Taiwan Centers for Disease Control grant United Biomedical, Inc., Asia (“UBI-Asia”), a related party through common ownership which is responsible for applying for and managing grants on the Company’s behalf, was awarded a grant by the Taiwan Centers for Disease Control (“Taiwan CDC”) for COVID-19 vaccine development. UBI-Asia contracted with the Company to conduct a two-phase study of a COVID-19 vaccine clinical trial in Taiwan. The grant provides that costs incurred to complete the two phases of the clinical trial will be reimbursed based on the achievement of certain milestones as defined in the agreement. At each reporting date, the Company assesses the status of all the activities involved in completing the clinical trials in relation to the milestones. The Company accounts for the amounts that have been received from the Taiwan CDC to reimburse costs incurred on the clinical trials and not expected to be refunded back to the Taiwan CDC as contra research and development expenses in the accompanying consolidated statements of operations.
Research and development	Research and development Research and development expenses include employee related costs, consulting, contract research, depreciation, rent, stock-based compensation and other corporate costs attributable to research and development activities and are expensed as incurred. The Company has entered into various research, development and manufacturing contracts, some of which are with related parties (see Note 18). These agreements are generally cancelable by either party, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. The Company’s historical accrual estimates have not been materially different from the actual costs.
Patent costs	Patent costs Patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty relating to the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.
Stock-based compensation	Stock-based compensation The Company measures all stock-based awards granted to employees, directors and non-employees based on the fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Prior to the Company's IPO in November 2021, there was no public market for the Company’s common stock and the estimated fair value of its common stock was determined by its most recently available third-party valuations of common stock. There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred securities, the superior rights and preferences of securities senior to the common securities at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering (“IPO”) or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.
Income taxes	Income taxes
Net loss per share	Net loss per share The Company follows the two-class method when computing net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated, and participation rights in undistributed earnings. The two-class method requires loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common stock. For purpose of this calculation, outstanding options, unvested restricted stock and convertible preferred stock are considered potential dilutive common stock and are excluded from the computation of net loss per share as their effect is anti-dilutive. The Company’s convertible preferred stock contractually entitles the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to be outstanding if their effect is anti-dilutive.

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Contractual Obligations The Company enters into agreements with contract research organizations (“CROs”) to conduct clinical trials and preclinical studies and contract manufacturing organizations (“CMOs”) to produce vaccines and other potential product candidates. Contracts with CROs and CMOs are generally cancellable, with notice, at the Company’s option. As of December 31, 2021, the Company had remaining prepayments to CROs of $ 1.6 million and remaining prepayments to CMOs of $ 2.5 million for activities associated with the conduct of its clinical trials and for the production of the Company’s anticipated vaccine product candidate. Michael J. Fox Foundation Grant On November 3, 2021, the Company was awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (“MJFF”) in the amount of $ 0.8 million to be used in a project for the exploration of markers for target engagement in individuals immunized with UB-312, an active a -Synuclein immunotherapy. The Company will oversee sample management, sample preparation (IgG fractions) and distribution, as well as characterize the binding properties of the antibodies against pathological forms of aSyn. As funding is expected to be utilized over a two-year period, as cash is received, the amount expected to the utilized within twelve months is recognized to short-term restricted cash/deposits, with a corresponding short-term accrued liability, which is released as the related expenses are offset. The Company recognizes payments from MJFF as a reduction of research and development expenses, in the same period as the expenses that the grant is intended to reimburse are incurred. The remaining balance of cash received is recognized to long-term restricted cash/deposits, with a corresponding long-term accrued liability. As of December 31, 2021, the balance of short-term restricted cash/deposits and the corresponding short-term accrued liability was $ 0 and the balance of long-term restricted cash/deposits and the corresponding long-term accrued liability was $ 0 . For the year ended December 31, 2021, the Company recognized less than $ 0.1 million as a reduction of research and development expenses for amounts reimbursed through the grant. Lease Agreements The Company has multiple operating lease agreements for office and laboratory space that extend through August 2022. The Company records total expense on a straight-line basis over the term of the lease agreement. One of the Company’s leases requires the Company to provide a security deposit in the amount of less than $ 0.1 million. The Company is also required to pay certain operating costs under its leases. Rent expense for each of the years ended December 31, 2021 and 2020 amounted to less than $ 0.1 million, and $ 0.1 million, respectively. In August 2021, the Company entered into a lease for 5,012 square feet of lab space with Space Florida in Exploration Park, Florida commencing August 12, 2021. The lease has an initial one-year term with an annual lease obligation of $ 0.2 million, after Lessee credits. License Agreements In October 2014, the Company entered into a contribution agreement with UBI, whereby UBI contributed and assigned to the Company assets and granted a non-exclusive license to certain technologies deemed necessary or reasonably useful in the utilization of the licensed intellectual property. In consideration, the Company issued 32,505,306 shares of common stock to UBI. The agreement allowed for exploitation of all diagnostic, prophylactic, and therapeutic uses and indications in humans in the field of neurology. The agreement was amended in August 2019 to provide the Company with exclusivity (except as to UBI) in the field of neurology and the flexibility to pursue indications outside the initial field limitations. In connection with the amendment, the Company agreed to execute an exclusive, worldwide license agreement for any product that is developed by the Company outside the original field. The terms and conditions are to be negotiated in good faith and mutually agreed upon. The Company anticipates that if it is required to enter into an exclusive license agreement, it will be able to negotiate financial terms for the license at prevailing market rates within the pharmaceutical industry. Accordingly, the Company may be required to pay UBI upfront fees, revenue royalties, development milestones, commercial milestones, sublicense fees, and other related fees. Vaxxinity’s COVAXX subsidiary was formed in March 2020 through a transfer of technology from UBI, UBI IP Holdings, and UBI US Holdings, LLC, all related parties of the Company, whereby the Company, pursuant to an April 2020 license agreement, obtained exclusive rights to intellectual property and technology related to the discovery of vaccines, diagnostic assays, and antigens for use against all coronaviruses including, without limitation, SARS, MERS, and COVID-19 in all strains in humans. The license is worldwide, perpetual, exclusive and fully paid-up. There are no future royalty or milestone payment obligations associated with the agreement. The Company has the right to grant sublicenses. The Company considered ASC 805, “Business Combinations” and ASC 730, “Research and Development” in determining how to account for the issuance of common stock. The license agreement is considered to be a common control transfer; however, the related party did not have any basis in the assets licensed, so there was no accounting impact for the Company. In August 2021, Vaxxinity entered into a license agreement (the “Platform License Agreement”) with UBI and certain of its affiliates that expanded intellectual property rights previously licensed under previously issued license agreements with UBI. As part of the agreement, Vaxxinity obtained a worldwide, sublicensable (subject to certain conditions), perpetual, fully paid-up, royalty-free license to research, develop, make, have made, utilize, import, export, market, distribute, offer for sale, sell, have sold, commercialize or otherwise exploit peptide-based vaccines in the field of all human prophylactic and therapeutic uses, except for such vaccines related to human immunodeficiency virus (HIV), herpes simplex virus (HSE) and Immunoglobulin E (IgE). The patents and patent applications licensed under the Platform License Agreement include claims directed to a CpG delivery system, artificial T helper cell epitopes and certain designer peptides and proteins utilized in UB-612. As described above, in consideration for the Platform License Agreement, the Company issued to UBI a warrant to purchase Class A common stock (the “UBI Warrant”). The Company considered ASC 805, “Business Combinations” (“ASC 805”) and ASC 730, “Research and Development” (“ASC 730”) in determining how to account for the issuance of the Class A common stock warrants. The Class A common stock warrants were issued to a related party in exchange for a license agreement. The majority of the voting interests in the related party and that of the Company were held by a group of immediate family members, at the time of the transaction, and as such the transaction constitutes a common control transaction, which requires the license to be accounted for at the carrying value in the books of the transferor. As the related party did not have any basis in the assets licensed, there was no accounting impact for the Company. In connection with preparing its financial statements for the fiscal year ended December 31, 2021, the Company identified an immaterial error relating to the recording of the UBI Warrant on its financial statements as of and for the nine months ended September 30, 2021. The UBI Warrant was recorded on the balance sheet as additional paid in capital and recognized as an ‘intangible asset – licensed intellectual property’ in the amount of $ 13.3 million, and $ 0.1 million was amortized in the nine months ended September 30, 2021. However, as noted above, the UBI Warrant was issued to a related party whose basis in the rights and licenses received pursuant to the Platform License Agreement was zero. As a result, the transaction should not have resulted in any accounting impact to the Company. The Company has concluded that the error is not material to any previously issued financial statements. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to employees, consultants, vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations, or cash flows, and it has not accrued any liabilities related to such obligations as of December 31, 2021. Legal Proceedings From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. As of December 31, 2021, the Company was not a party to any material legal matters or claims.

Subsequent Events (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 $ / shares shares
Subsequent Event [Line Items]
Options issued	13,482,915	2,672,152
Options issued, exercise price \| $ / shares	$ 8.20	$ 1.17
Reverse stock split	1.556
Issuance of stock \| $	$ 103
Shares issued	32,505,306
Common Class A [Member]
Subsequent Event [Line Items]
Shares issued	6,000,000

Summary of Significant Accounting Policies (Useful Life of Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2021
Air Transportation Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Equity Incentive Plans (Tables)	12 Months Ended
Equity Incentive Plans (Tables)	Dec. 31, 2021
Equity Incentive Plan [Abstract]
Weighted Average Assumptions	December 31, 2021 2020 Risk-free interest rate 0.59% - 1.35% 0.34% - 0.38% Expected term (in years) 5.00 - 6.30 5.60 - 6.08 Expected volatility 71.60% - 93.40% 70.90% - 86.84% Expected dividend yield 0.00% 0.00%
Summary of Stock Option Activity	Number of Stock Options Outstanding Weighted Price Per Share Weighted Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2019 7,610,289 $ 0.33 8.6 $ 2,357 Granted 2,672,152 1.17 Exercised (283,290) 0.29 Forfeited (722,752) 0.29 Balance at December 31, 2020 9,276,399 $ 0.60 7.6 $ 8,415 Granted 13,482,915 8.20 Exercised (186,204) 0.91 Forfeited (1,185,201) 2.98 Balance at December 31, 2021 21,387,909 $ 5.25 7.4 $ 49,684 Options vested and exercisable at December 31, 2021 13,439,566 $ 4.40 6.8 $ 37,969
Summary of Restricted Stock Activity	Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2020 15,405 $ 0.50 Vested (15,405) (0.50) Unvested at December 31, 2021 — $ —
Schedule of Stock-Based Compensation Expense for Stock Options	Years Ended December 31, 2021 2020 Research and development $ 1,343 $ 243 General and administrative 29,069 771 Total stock-based compensation expense $ 30,412 $ 1,014

Summary of Significant Accounting Policies (Summary of Restatement-Statement of Cash Flows) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Net loss	$ (137,175)	$ (39,957)
Depreciation	1,102	717
Stock-based compensation expense	280	0
Non-cash interest expense	0	582
Change in fair value of convertible notes	2,667	5,761
Accounts receivable	26	(26)
Prepaid expenses and other current assets	(4,704)	(3,488)
Accounts payable	2,174	(267)
Amounts due to related parties	(31)	(1,743)
Accrued expenses and other current liabilities	1,775	285
Other liabilities	(12)	94
Net cash used in operating activities	(80,990)	(33,910)
Purchase of property and equipment	(1,318)	(1,477)
Net cash used in investing activities	(1,318)	(1,477)
Proceeds from issuance of convertible notes payable with related parties	2,000	12,040
Proceeds from Paycheck Protection Program	257	0
Proceeds from exercise of stock options	79	170
Net cash provided by financing activities	66,109	196,167
Increase in cash, cash equivalents, and restricted cash	30,722	113,859
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance	31,198	476
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	$ 145,057	$ 31,198

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2021
Common Stock [Abstract]
Common Stock	12. Common Stock As explained in Note 1, in accordance with the Contribution and Exchange Agreement, on March 2, 2021, all outstanding shares of common stock of UNS and COVAXX were contributed to Vaxxinity and exchanged for an aggregate of 60,360,523 shares of Vaxxinity’s Class A common stock and 10,999,149 shares of Vaxxinity’s Class B common stock. Each UNS share of common stock was exchanged for 0.2191 shares of Vaxxinity common stock and each share of COVAXX common stock was exchanged for 3.4233 shares of Vaxxinity common stock. In June 2021, the Company converted 2,874,983 shares of Class A common stock held by the Company’s Chief Executive Officer and Executive Chairman on a one-to-one basis for shares of Class B common stock. As of December 31, 2021, Vaxxinity’s Amended and Restated Certificate of Incorporation authorized 1,100,000,000 shares of common stock with a par value of $ 0.0001 per share, of which 1,000,000,000 shares have been designated as Class A common stock and 100,000,000 shares have been designated as Class B common stock. Holders of Class A common stock and Class B common stock have identical rights, except with respect to voting and conversion. Except as otherwise expressly provided in Vaxxinity’s Amended and Restated Certificate of Incorporation or Bylaws, or required by applicable law, holders of Class A common stock will be entitled to one vote per share on all matters submitted to a vote of stockholders and holders of our Class B common stock will be entitled to ten votes per share on all matters submitted to a vote of stockholders. Holders of Class A common stock and Class B common stock vote together as a single class on all matters submitted to a vote of stockholders, except (i) amendments to Vaxxinity’s Amended and Restated Certificate of Incorporation to increase or decrease the par value of a class of capital stock, in which case the applicable class would be required to vote separately to approve the proposed amendment and (ii) amendments to Vaxxinity’s Amended and Restated Certificate of Incorporation that alter or change the powers, preferences or special rights of a class of capital stock in a manner that affects its holders adversely, in which case the applicable class would be required to vote separately to approve the proposed amendment. Holders of common stock are entitled to receive, ratably, dividends as may be declared by Vaxxinity’s board of directors out of funds legally available therefor if the board of directors, in its discretion, determines to issue dividends. The voting, dividend, and liquidation rights of the holders of common stock are subject to and qualified by the rights, powers, and preferences of the holders of Vaxxinity’s preferred stock. The Company has reserved shares of common stock for issuance for the following purposes: December 31, 2021 2020 Series Seed preferred — 7,831,528 Series Seed-1 preferred — 22,876,457 Series Seed-2 preferred — 14,615,399 Series A-1 preferred — 1,871,511 Series A-2 preferred — 6,307,690 Options issued and outstanding 21,387,909 9,276,399 Options available for future grants 7,209,538 1,897,049 Warrants issued and outstanding 1,928,020 86,186 30,525,467 64,762,219

Notes payable (Notes payable with related parties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Repayment	$ (414)	$ (202)
Additions	(31)	(1,743)
2019 Related Notes and 2020 Executive Note [Member]
Debt Instrument [Line Items]
Beginning balance	2,294	2,188
Debt Instrument Increase Accrued Interest	19
Repayment	(100)
Interest paid	(8)
Conversion	(2,205)
Additions		106
Ending balance	0	2,294
2019 Related Notes and 2020 Executive Note [Member] \| Principal Amount [Member]
Debt Instrument [Line Items]
Beginning balance	2,100	2,100
Debt Instrument Increase Accrued Interest	0
Repayment	(100)
Interest paid	0
Conversion	(2,000)
Additions		0
Ending balance	0	2,100
2019 Related Notes and 2020 Executive Note [Member] \| Accrued Interest [Member]
Debt Instrument [Line Items]
Beginning balance	194	88
Debt Instrument Increase Accrued Interest	19
Repayment	0
Interest paid	(8)
Conversion	(205)
Additions		106
Ending balance	$ 0	$ 194

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation The accompanying consolidated financial statements have been prepared using generally accepted accounting principles in the United States of America (GAAP) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial reporting. The consolidated financial statements for the periods presented include the accounts of UNS and COVAXX that were parties to the Contribution and Exchange Agreement. All share and per share amounts, as originally recorded by each entity, have been converted to a number of shares and per share amounts using the conversion ratios determined under the Contribution and Exchange Agreement and the Stock Split ratio. Foreign currency translation The Company’s consolidated financial statements are prepared in U.S. dollars. Its foreign subsidiaries use the U.S. dollar as their functional currency and maintain their records in the local currency. Nonmonetary assets and liabilities are re-measured at historical rates and monetary assets and liabilities are re-measured at exchange rates in effect at the end of the reporting period. Income statement accounts are re-measured at average exchange rates for the reporting period. The resulting gains or losses are included in foreign currency (losses) gains in the consolidated statements of operations. Segment information Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company has determined that it operates as a single operating segment and has one reportable segment. Use of estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates contained within these consolidated financial statements include, but are not limited to, the estimated fair value of the Company’s common stock and convertible notes payable, simple agreements for future equity, warrant liabilities, stock-based compensation, income tax valuation allowance and the accruals of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in facts and circumstances. Actual results may differ materially from those estimates or assumptions. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents, including balances held in the Company’s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time may exceed the U.S. federally insured limits. The objectives of the Company’s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company’s cash flow requirements, and to attain a market rate of return. Restricted cash Concentration of credit risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company is dependent on contract manufacturers, several of whom are considered to be related parties, for manufacturing, quality control, testing, validation and supply services, including production, including production and shipment of its enzyme-linked immunosorbent assay (“ELISA”) tests, and for research and development and clinical activities. The Company’s future revenue as well as research and development programs could be adversely affected by a significant supply interruption by one or more of its contract manufacturers. Accounts receivable The Company’s trade accounts receivable consist of amounts due from distributors. The Company reserves against trade accounts receivable for estimated losses that may arise from a customer’s inability to pay, and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. As of December 31, 2021 and 2020, the Company has not recorded any allowance for bad debts against the trade accounts receivable. Property and equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the assets. The estimated useful life of property and equipment is as follows: Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in gain or loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred. Impairment of long-lived assets Long-lived assets, comprised of property and equipment, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses or disposals on long-lived assets. Deferred offering costs The Company capitalizes certain legal, audit, accounting and other third-party fees that are directly associated with an in-process capital financing effort as deferred offering costs until such financing is consummated. After consummation of the financing, these costs are recorded as a reduction of additional paid-in capital generated as a result of the financing. Should the financing be abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the statement of operations. Fair value measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets that are identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Prior to the conversion in accordance with the Contribution and Exchange Agreement, the majority of the Company’s convertible notes and all of the simple agreement for future equity (“SAFE”) and warrant liabilities were carried at fair value and were classified as Level 3 liabilities. Convertible notes payable The Company issued convertible notes payable at various times from 2014 to 2021. The Company accounts for the convertible notes payable at fair value in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”). The notes payable with related parties are accounted for as straight debt under ASC 470, Debt (“ASC 470”). The Company has elected to separate interest expense from the full change in fair value of the convertible notes. Debt issuance costs incurred by the Company are amortized to interest expense over the term of the convertible notes using the effective interest method in the accompanying consolidated statements of operations. On March 2, 2021, each convertible note that was outstanding was exchanged for shares of Series A preferred stock (see Note 8). Debt issuance costs The Company records debt issuance costs as a reduction to the carrying value of the debt. The debt discounts are amortized over the term of the debt using the effective interest method and recognized as interest expense in the accompanying consolidated statement of operations. Simple Agreement for Future Equity—SAFE The Company accounts for SAFEs at fair value in accordance with ASC 480. The SAFEs are subject to revaluation at the end of each reporting period, with changes in fair value recognized in the accompanying consolidated statements of operations. On March 2, 2021, each SAFE that was outstanding was converted into shares of the Company’s Series A preferred stock (see Note 11). Classification of convertible preferred stock The Company records all convertible preferred stock at its original issuance price, less direct and incremental issuance costs, as stipulated by its terms. The Company’s convertible preferred stock is classified outside of stockholders’ deficit because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company. All shares of the Company’s Series A and Series B preferred stock converted into shares of the Company’s Class A common stock concurrently with the closing of the initial public offering (see Note 10). Revenue recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts With Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled to in exchange for those goods or services. The Company applies ASC 606 to contracts with customers only when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by evaluating whether each promised good or service is distinct. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services, the intended benefit of the contract and whether each good or service is separately identifiable from the other aspects of the contractual relationship. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the most likely amount method and applies the constraint on variable consideration, which requires the amount included in the transaction price to be constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and, if over time, recognition is based on the use of an output or input method. In the Company’s sole revenue contract, the performance obligation was satisfied at the point in time the data and related samples were made available for the customer’s review. For its sales of ELISA tests, the Company recognizes revenue once control is transferred upon delivery to the customer. Taiwan Centers for Disease Control grant United Biomedical, Inc., Asia (“UBI-Asia”), a related party through common ownership which is responsible for applying for and managing grants on the Company’s behalf, was awarded a grant by the Taiwan Centers for Disease Control (“Taiwan CDC”) for COVID-19 vaccine development. UBI-Asia contracted with the Company to conduct a two-phase study of a COVID-19 vaccine clinical trial in Taiwan. The grant provides that costs incurred to complete the two phases of the clinical trial will be reimbursed based on the achievement of certain milestones as defined in the agreement. At each reporting date, the Company assesses the status of all the activities involved in completing the clinical trials in relation to the milestones. The Company accounts for the amounts that have been received from the Taiwan CDC to reimburse costs incurred on the clinical trials and not expected to be refunded back to the Taiwan CDC as contra research and development expenses in the accompanying consolidated statements of operations. Research and development Research and development expenses include employee related costs, consulting, contract research, depreciation, rent, stock-based compensation and other corporate costs attributable to research and development activities and are expensed as incurred. The Company has entered into various research, development and manufacturing contracts, some of which are with related parties (see Note 18). These agreements are generally cancelable by either party, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. The Company’s historical accrual estimates have not been materially different from the actual costs. Patent costs Patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty relating to the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. Stock-based compensation The Company measures all stock-based awards granted to employees, directors and non-employees based on the fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Prior to the Company's IPO in November 2021, there was no public market for the Company’s common stock and the estimated fair value of its common stock was determined by its most recently available third-party valuations of common stock. There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred securities, the superior rights and preferences of securities senior to the common securities at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering (“IPO”) or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. The fair value of each restricted stock award is estimated on the date of grant based on the fair value of the Company’s common stock on that same date. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model (“Black-Scholes”), which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. The Company, both prior to and after the IPO in November 2021, lacks sufficient company-specific historical and implied volatility information for its stock, and therefore estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Performance-based options The Company accounts for performance-based options according to the ASC 718, Compensation – Stock Compensation ("ASC 718"), which are subject to different accounting depending on whether they meet the definition of performance conditions, market conditions, or other conditions. The conditions present in the Company's grants contain both performance and market conditions. The effect of each condition is reflected in the grant-date fair value and the performance-based options are measured considering the probability of satisfying the performance and market conditions. The Company has used a Monte Carlo Simulation Model to calculate the fair value of the performance condition (the completion of the IPO) and market condition (the 25% higher value after the IPO condition). The performance condition was determined to not be probable at the time of the grant date, and the recognition of compensation cost was deferred until the IPO was consummated in November 2021. The recognition of expense for the portion of the grant-date fair value assigned to the market condition will be recognized as expense according to the derived service period in the valuation model. Income taxes The Company accounts for income taxes according to the ASC 740, Income Taxes (“ASC 740”) using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. In evaluating its ability to recover its deferred tax assets, the Company considers all available positive and negative evidence, including projected future taxable income, prudent and feasible tax planning strategies and recent financial operations. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To the extent the Company determines that such tax positions will not be sustained, the provision for income taxes would include the effects of any resulting income tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. Net loss per share The Company follows the two-class method when computing net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated, and participation rights in undistributed earnings. The two-class method requires loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common stock. For purpose of this calculation, outstanding options, unvested restricted stock and convertible preferred stock are considered potential dilutive common stock and are excluded from the computation of net loss per share as their effect is anti-dilutive. The Company’s convertible preferred stock contractually entitles the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to be outstanding if their effect is anti-dilutive. Emerging growth company status The Company is an “emerging growth company” (“EGC”), as defined in the Jumpstart Our Business Startups Act (“JOBS Act”) and is permitted to and plans to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, as long as the Company remains an EGC, it will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not EGCs. December 31, 2021 2020 Cash and cash equivalents $ 144,885 $ 31,143 Restricted cash 172 55 Total cash, cash equivalents and restricted cash $ 145,057 $ 31,198 Estimated Useful Life Airplane 15 years Facilities 15 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	18. Related Party Transactions The Company has a Related Party policy which defines related parties, and assigns oversight responsibility for related party transactions to the Company's Audit Committee. The Committee reviews in advance related party transactions, and considers multiple factors, including the proposed aggregate value of the transaction, or, in the case of indebtedness, the amount of principal that would be involved, the benefits to the Company of the proposed transaction, the availability of other sources of comparable products or services, and an assessment of whether the proposed transaction is on terms that are comparable to the terms available to or from, as the case may be, unrelated third parties. Under the policy, related party transactions are approved only if the Committee determines in good faith that the transaction is not inconsistent with the interests of the Company and its shareholders. The Company has related party arrangements with UBI and a number of its affiliated companies listed namely, United Biomedical, Inc., Asia (“UBI-Asia”), UBI Pharma, Inc. (“UBI-P”), United BioPharma, Inc (“UBP”) and UBI IP Holding (“UBI-IP”). As of December 31, 2021 UBI owned 43 % of the Company’s stock on an as converted basis. The majority of the voting interests in both UBI and the Company were held by a group of immediate family members, and as such the entities are under common control. These related parties are governed by various Master Services Agreements (“MSA”) detailed below. UBI MSA - UBI provides research, development and clinical functions to the Company. There is also a purchase arrangement with UBI for the production and shipment of the Company’s diagnostic test kits. UBIA MSA - UBI-Asia for manufacturing, quality control, testing, validation, and supply services. UBP MSA - United BioPharma, Inc provide the Company with manufacturing, testing and validation. COVID MSA (“COVID MSA”) - COVID MSA provides that UBI acts as COVAXX’s agent with respect to matters relating the Company’s COVID-19 program and provides research, development, manufacturing and back office administrative services to the Company. COVID-19 Relief MSA - A four-company MSA with UBI, UBI-Asia and UBP. The Company is an exclusive licensee of technologies related to diagnostics, vaccines, and therapies for COVID-19. The MSA established the terms under which UBI-Asia provides research, development, testing and manufacturing services to the Company and UBP provides contract development and manufacturing services to the Company. Total amounts due to related parties were $ 19.4 million and $ 8.0 million as of December 31, 2021 and 2020, respectively. Total amounts due from related parties were $ 0.4 million and $ 0.4 million as of December 31, 2021 and December 31, 2020, respectively. Total service fees incurred were $ 35.4 million and $ 18.2 million for the years ended December 31, 2021 and 2020, respectively. Taiwan Centers for Disease Control Grant (“Taiwan CDC”) UBI-Asia, which is responsible for applying for and managing grants on our behalf under the COVID-19 program, was awarded a grant by the Taiwan CDC for COVID-19 vaccine development. The Company contracted with UBI-Asia to conduct a two-phase study of a COVID-19 vaccine clinical trial in Taiwan. The grant provides that costs incurred to complete the two phases of the clinical trial will be reimbursed based on the achievement of certain milestones as provided in the agreement. The Company provides administrative services to UBI-IP. Under the arrangement, the Company issues vendor payments and provides technical services mostly for legal services on behalf UBI-IP. The Company bills UBI-IP for services based on the costs incurred with no markup. Total related party operating activity, including the activity described above, for the years ended December 31, 2021 and 2020 are as follows (in thousands): December 31, 2021 2020 Consolidated balance sheet Assets Prepaid expenses and other current assets $ 3,517 $ 2,867 Property and equipment, net 337 725 Accrued expenses — 285 Amounts due from related parties 393 361 Liabilities Amounts due to related parties 19,407 8,004 Years Ended December 31, 2021 2020 Consolidated statement of operations Revenue $ — $ 162 Cost of revenue — 52 Operating expenses Research and development Services provided by related parties 41,430 17,987 Taiwan CDC grant reimbursement from related party (7,199) (2,948) General and administrative Services provided by related parties 1,173 3,147

Property and Equipment (Property and Equipment, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 14,154	$ 13,036
Less accumulated depreciation	(1,981)	(878)
Property and equipment, net	12,173	12,158
Air Transportation Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	11,983	11,983
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,831	969
Software And Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	168,000	0
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	87,000	0
Furniture And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 85,000	$ 84,000

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2021
Property and Equipment [Abstract]
Property and Equipment, Net	December 31, 2021 2020 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 1,831 969 Software 168 — Vehicles 87 — Facilities, furniture and fixtures 85 84 Total property and equipment 14,154 13,036 Less: accumulated depreciation (1,981) (878) Property and equipment, net $ 12,173 $ 12,158

Fair Value Measurements (Schedule of Activity in Level 3, Warrants) (Details) - Level 3 [Member] - Warrants [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 400	$ 0
Issuance of Series A-1 preferred warrants		573
Change in fair value	214	41
Conversion Of Warrants	(614)	(214)
Balance	$ 0	$ 400

Other Long-Term Liabilities	12 Months Ended
Other Long-Term Liabilities	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	7. Other Long-Term Liabilities Other long-term liabilities consisted of the following (in thousands): December 31, 2021 2020 Accrued tax provision 236 236 Accrued rent 1 13 $ 237 $ 249 As of December 31, 2021 and 2020, approximately $ 0.2 million of the accrued tax provision relates to penalties and interest the Company may be subject to paying for late filing fees related to a foreign subsidiary. The Company expects these amounts to be forgiven but has accrued for them until the statute of limitations expires and it is appropriate to write them off.

Convertible Preferred Stock	12 Months Ended
Convertible Preferred Stock	Dec. 31, 2021
Convertible preferred stock [Abstract]
Convertible preferred stock	10. Convertible Preferred Stock In connection with the Reorganization, each UNS convertible preferred share was exchanged for 0.2191 shares of Vaxxinity preferred stock and each share of COVAXX convertible preferred stock was exchanged for 3.4233 shares of Vaxxinity preferred stock. During the first and second quarters of 2021, the Company raised gross proceeds of $ 122.8 million in connection with its Series B preferred stock financing. The Company issued a total of 15,365,574 shares at a price of $ 8.00 per share. All shares of the Company’s Series B preferred stock converted into shares of the Company’s Class A common stock concurrently with the closing of the initial public offering. As of December 31, 2021, Vaxxinity’s Amended and Restated Certificate of Incorporation authorized 50,000,000 shares of preferred stock with a par value of $ 0.0001 per share. The table below details the Company's Class A common stock which was issued upon conversion of Series A and Series B preferred stock concurrently with the closing of the IPO in November 2021. The common stock issued upon conversion reflects the application of the stock split described in Note 1.

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Restricted cash	December 31, 2021 2020 Cash and cash equivalents $ 144,885 $ 31,143 Restricted cash 172 55 Total cash, cash equivalents and restricted cash $ 145,057 $ 31,198
Useful life of property and equipment	Estimated Useful Life Airplane 15 years Facilities 15 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2021
Property and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Property and equipment, net consisted of the following (in thousands): December 31, 2021 2020 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 1,831 969 Software 168 — Vehicles 87 — Facilities, furniture and fixtures 85 84 Total property and equipment 14,154 13,036 Less: accumulated depreciation (1,981) (878) Property and equipment, net $ 12,173 $ 12,158

Accrued Expenses and Other Current Liabilities	12 Months Ended
Accrued Expenses and Other Current Liabilities	Dec. 31, 2021
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 2021 2020 Accrued bonuses $ 2,294 $ 2,187 Accrued external research and development 1,501 296 Accrued professional fees and other 692 228 Accrued interest 32 33 $ 4,519 $ 2,744

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Income tax expense	$ 0	$ 0
Valuation allowance increase	20,900	$ 6,700
Unrecognized tax benefits that would impact effective tax rate	$ 100
Effective Income Tax Rate Continuing Operations	0.00%	0.00%
Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate	$ 600
Income Tax Examination Penalties And Interest Accrued	200
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	44,500	$ 134,600
Foreign [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 24,000	$ 20,200

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 144,885	$ 31,143
Accounts receivable	0	26
Amounts due from related parties	393	361
Prepaid expenses and other current assets	8,851	4,144
Total current assets	154,129	35,674
Deferred offering costs	0	2,254
Property and equipment, net	12,173	12,158
Restricted cash	172	55
Total assets	166,673	50,141
Current liabilities:
Accounts payable	3,192	1,017
Amounts due to related parties	19,407	8,004
Accrued expense and other current liabilities	4,519	2,744
Notes payable	376	619
Notes payable with related parties	0	2,294
Convertible notes payable	0	10,356
Convertible notes with related parties, net of discount	0	14,324
Total current liabilities	27,494	39,358
Other liabilities
Simple agreement for future equity	0	24,335
Notes payable, net of current portion	10,323	10,699
Warrant liability	0	400
Other long-term liabilities	237	249
Total liabilities	38,054	75,041
Preferred stock	0	0
Stockholders equity (deficit)
Class A treasury stock, par value of $0.0001; 0 and shares at December 31, 2021 and 2020, respectively	0	(23)
Additional paid-in capital	357,822	4,682
Accumulated deficit	(229,481)	(92,306)
Total stockholders equity (deficit)	128,619	(87,375)
Total liabilities, convertible preferred stock, and stockholders equity (deficit)	166,673	50,141
Convertible Preferred Stock [Member]
Other liabilities
Preferred stock	0	62,475
Series Seed Stock [Member]
Other liabilities
Preferred stock	0	10,383
Series Seed-1 Stock [Member]
Other liabilities
Preferred stock	0	20,903
Series Seed-2 Stock [Member]
Other liabilities
Preferred stock	0	11,315
Series A-1 Stock [Member]
Other liabilities
Preferred stock	0	4,640
Series A-2 Stock [Member]
Other liabilities
Preferred stock	0	15,234
Series A Preferred Stock [Member]
Other liabilities
Preferred stock	0	0
Series B Preferred Stock [Member]
Other liabilities
Preferred stock	0	0
Class A Common Stock [Member]
Stockholders equity (deficit)
Common stock:	278	272
Common Class B [Member]
Stockholders equity (deficit)
Common stock:	$ 0	$ 0

Income Taxes (Schedule of Loss Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
United States	$ (128,538)	$ (31,053)
Foreign	(8,636)	(8,904)
Total	$ (137,175)	$ (39,957)

Property and Equipment (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Depreciation	$ 1,102	$ 717

Accrued Expenses and Other Current Liabilities (Accrued Expenses and Other Current Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued payroll and benefits	$ 2,294	$ 2,187
Accrued External Research And Development	1,501	296
Accrued professional fees and other	692	228
Accrued interest	32	33
Total	$ 4,519	$ 2,744

Notes payable (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Proceeds from issuance of convertible notes payable with related parties	$ 2,000	$ 12,040
Payments Of Debt Issuance Costs	300	0
2018 Related Notes and Reorg. Convertible Notes [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties				$ 2,000
Debt Instrument Interest Rate Stated Percentage				5.00%
Interest Expense, Debt	100	100
2019 Executive Note [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties			$ 100
Debt Instrument Interest Rate Stated Percentage			5.00%
Notes Payable, Airplane [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties		$ 11,500
Debt Instrument Interest Rate Stated Percentage		3.40%
Interest Expense, Debt	400	$ 200
Debt Instrument Periodic Payment Interest		70
Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid	9,400
Payments Of Debt Issuance Costs		$ 300
Debt Instrument Increase Accrued Interest	100
Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties	$ 300

Convertible Preferred Stock (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Aug. 31, 2020
Class Of Stock [Line Items]
ConvertiblePreferredStockSharesIssuedUponConversion	3.4233
Preferred stock, shares authorized/designated	50,000,000	57,298,376
Preferred stock, par value	$ 0.0001	$ 0.0001
Safe 2 [Member]
Class Of Stock [Line Items]
Share Price			$ 2.3241
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, shares issued	0	0
Preferred stock, shares authorized/designated	0	0
Amended Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, shares issued	15,365,574
Proceeds from Issuance Initial Public Offering	$ 122.8
Share Price	$ 8.00
ConvertiblePreferredStockSharesIssuedUponConversion	3.4233
Preferred stock, shares authorized/designated	50,000,000
Preferred stock, par value	$ 0.0001

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized/designated	50,000,000	57,298,376
Series Seed Stock [Member]
Preferred stock, shares authorized/designated	0	7,831,528
Preferred stock, shares issued	0	10,452
Preferred stock, share outstanding	0	10,452
Series Seed-1 Stock [Member]
Preferred stock, shares authorized/designated	0	23,021,458
Preferred stock, shares issued	0	22,876,457
Preferred stock, share outstanding	0	22,876,457
Preferred stock, liquidation preference	$ 0	$ 20,964,000
Series Seed-2 Stock [Member]
Preferred stock, shares authorized/designated	0	14,615,399
Preferred stock, shares issued	0	14,615,399
Preferred stock, share outstanding	0	14,615,399
Preferred stock, liquidation preference	$ 0	$ 11,360,000
Series A-1 Stock [Member]
Preferred stock, shares authorized/designated	0	5,522,300
Preferred stock, shares issued	0	1,871,511
Preferred stock, share outstanding	0	1,871,511
Preferred stock, liquidation preference	$ 0	$ 5,210,000
Series A-2 Stock [Member]
Preferred stock, shares authorized/designated	0	6,307,690
Preferred stock, shares issued	0	6,307,690
Preferred stock, share outstanding	0	6,307,690
Preferred stock, liquidation preference	$ 0	$ 14,660,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized/designated	0	0
Preferred stock, shares issued	0	0
Preferred stock, share outstanding		0
Preferred stock, liquidation preference	$ 0	$ 0
Series B Preferred Stock [Member]
Preferred stock, shares authorized/designated	0	0
Preferred stock, shares issued	0	0
Preferred stock, share outstanding	0	0
Preferred stock, liquidation preference	$ 0	$ 0
Class A Common Stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	129,916,912
Common stock, shares issued	111,518,094	60,360,523
Common stock, shares outstanding	111,518,094	60,360,523
Treasury stock, shares	0	3,169,093
Common Class B [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	10,999,149
Common stock, shares issued	13,874,132	10,999,149
Common stock, shares outstanding	13,874,132	10,999,149

Equity Incentive Plan (Summary of Restricted Stock Activity) (Details)	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Equity Incentive Plan [Abstract]
Unvested, Number of Shares, Begining Balance \| shares	15,405
Vested, Number of Shares \| shares	(15,405)
Unvested, Number of Shares, Ending Balance \| shares	0
Unvested, Weighted average grant date fair value per share, beginning balance \| $ / shares	$ 0.50
Vested, weighted average grant date fair value per share \| $ / shares	(0.50)
Unvested, Weighted average grant date fair value per share, ending balance \| $ / shares	$ 0

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements of Income [Abstract]
Revenue	$ 66	$ 557
Cost of revenue	1,937	52
Gross (loss) profit	(1,871)	505
Operating expenses:
Research and development	71,379	20,570
General and administrative	51,825	12,217
Total operating expenses	123,204	32,787
Loss from operations	(125,075)	(32,282)
Other (income) expense:
Interest expense, net	840	1,182
Change in fair value of convertible notes	2,667	5,761
Change in fair value of simple agreements for future equity	8,365	615
Change in fair value of warrant liability	214	41
Loss on foreign currency translation, net	(23)	(77)
Other (income) expense	12,100	7,675
Loss before income taxes	(137,175)	(39,957)
Provision for income taxes	0	0
Net loss	$ (137,175)	$ (39,957)
Net loss per share, basic and diluted	$ (1.79)	$ (0.61)
Weighted average common shares outstanding, basic and diluted	76,586,842	65,638,946

Simple Agreement for Future Equity	12 Months Ended
Simple Agreement for Future Equity	Dec. 31, 2021
Simple Agreement for Future Equity [Abstract]
Simple Agreement for Future Equity	11. Simple Agreement for Future Equity—SAFE During the years ended December 31, 2021 and 2020, the Company executed SAFE arrangements. The SAFEs were not mandatorily redeemable, nor did they require the Company to repurchase a fixed number of shares. The Company determined that the SAFEs contained a liquidity event provision that embodied an obligation indexed to the fair value of the Company’s equity shares and could require the Company to settle the SAFE obligation by transferring assets or cash. For this reason, the Company recorded the SAFEs as a liability under ASC 480 and re-measured the fair value at the end of each reporting period, with changes in fair value reported in earnings. In March 2020, the Company issued a SAFE (“SAFE 1”) for $ 0.4 million, which converted into 463,162 shares of Series Seed-2 convertible preferred stock at $ 0.7773 per share in April 2020. In June, July, and August 2020, the Company issued a series of SAFEs (“SAFE 2”) for $ 14.7 million, which converted into 6,307,690 shares of Series A-2 convertible preferred stock (“Series A-2 preferred”) at $ 2.3241 per share in August 2020. The Company determined the fair value of SAFE 2 investment on the date of conversion and recognized the difference between the fair value on the date of conversion and the initial fair value of SAFE 2 investment in the consolidated statements of operations. In December 2020, the Company issued a series of SAFEs (collectively, “SAFE 3”) for $ 24.3 million. In January 2021, the Company issued additional SAFEs for $ 2.9 million which had the same terms as SAFE 3. Key provisions of SAFE 3 are as follows: Equity Financing —Upon initial closing of a qualified financing of at least $ 50.0 million, SAFE 3 will automatically convert into the greater of (1) the number of shares of SAFE 3 preferred stock equal to the purchase amount divided by the SAFE 3 price, defined as the price per share equal to the post-money valuation divided by all shares outstanding, all convertible securities, all issued, outstanding and promised options, and the unissued option pool, or (2) the number of shares of SAFE 3 preferred stock equal to the purchase amount divided by the discount price, defined as the price per share of the standard preferred stock sold in a qualified financing multiplied by eighty percent (80%). Liquidity Event —If there is a liquidity event, as defined, before the termination of SAFE 3, SAFE 3 will automatically be entitled to receive a portion of proceeds, subject to the liquidation priority set forth in the agreement, due and payable immediately prior to, or concurrent with, the consummation of such liquidity event, equal to the greater of (i) the purchase amount or (ii) the amount payable on the number of shares of common stock equal to the purchase amount divided by the liquidity price, as outlined in the agreements. Dissolution Event —If there is a dissolution event, as described in the agreements, before the termination of SAFE 3, the investor will automatically be entitled, subject to the liquidation priority set forth in the agreement, to receive a portion of proceeds equal to the purchase amount, due and payable to the investor immediately prior to the consummation of the dissolution event. Termination —SAFE 3 will automatically terminate immediately following the earliest to occur of: (i) the issuance of capital stock to the investor pursuant to the automatic conversion provisions of SAFE 3 or (ii) the payment, or setting aside for payment, of amounts due the investor. In connection with the Contribution and Exchange Agreement, the holders of SAFEs agreed to convert such SAFEs into shares of Series A-3 preferred stock of COVAXX, which shares were then exchanged for shares of Vaxxinity’s preferred stock. The SAFEs were converted into shares of the Company’s Series A preferred stock pursuant to the Contribution and Exchange Agreement. Prior to the Reorganization, all the holders of outstanding COVAXX SAFEs agreed to convert such SAFEs into shares of Series A-3 preferred stock of COVAXX, which shares were then exchanged for shares of the Company’s Series A preferred stock.

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies [Abstract]
Restricted cash	$ 172	$ 55
Lessee, Lease, Description [Line Items]
Operating Lease Liability	$ 200

Equity Incentive Plan	12 Months Ended
Equity Incentive Plan	Dec. 31, 2021
Equity Incentive Plan [Abstract]
Equity Incentive Plan	December 31, 2021 2020 Risk-free interest rate 0.59% - 1.35% 0.34% - 0.38% Expected term (in years) 5.00 - 6.30 5.60 - 6.08 Expected volatility 71.60% - 93.40% 70.90% - 86.84% Expected dividend yield 0.00% 0.00% Number of Stock Options Outstanding Weighted Price Per Share Weighted Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2019 7,610,289 $ 0.33 8.6 $ 2,357 Granted 2,672,152 1.17 Exercised (283,290) 0.29 Forfeited (722,752) 0.29 Balance at December 31, 2020 9,276,399 $ 0.60 7.6 $ 8,415 Granted 13,482,915 8.20 Exercised (186,204) 0.91 Forfeited (1,185,201) 2.98 Balance at December 31, 2021 21,387,909 $ 5.25 7.4 $ 49,684 Options vested and exercisable at December 31, 2021 13,439,566 $ 4.40 6.8 $ 37,969 Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2020 15,405 $ 0.50 Vested (15,405) (0.50) Unvested at December 31, 2021 — $ — Years Ended December 31, 2021 2020 Research and development $ 1,343 $ 243 General and administrative 29,069 771 Total stock-based compensation expense $ 30,412 $ 1,014 13. Equity Incentive Plan Stock Options In March 2021, the Company replaced the 2017 and 2020 Stock Option and Grant Plans with the newly-adopted 2021 Stock Option and Grant Plan (the “Existing 2021 Plan”), which provided for the Company to grant qualified incentive options, nonqualified options, restricted stock awards, unrestricted stock awards, and restricted stock units to employees and non-employees to purchase the Company’s Class A common stock. The Existing 2021 Plan authorized the issuance of up to 21,593,830 shares of Class A common stock pursuant to awards. In August 2021, the Company canceled existing options to purchase, in aggregate, 6,362,455 shares of Class A common stock in exchange for an equal number of options to purchase shares of Class B common stock. The Company accounted for this exchange as a stock option modification. In November 2021, the Company replaced the Existing 2021 Plan with the 2021 Omnibus Incentive Compensation Plan (the “New 2021 Plan”), which provides for the Company to grant nonqualified stock options, incentive (qualified) stock options, stock appreciation rights, restricted share awards, restricted stock units, performance awards, cash incentive awards and other equity-based awards (including fully vested shares). The New 2021 Plan replaced the Existing 2021 Plan and no further grants will be made under the Existing 2021 Plan. The following is a summary of certain terms and conditions of the New 2021 Plan. The maximum number of shares of common stock that can be issued under the New 2021 Plan is 8,700,000 shares of Class A shares. As of December 31, 2021, 7,209,538 shares were available for future grant. Shares that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of stock, withheld to cover the exercise price or tax withholdings, or otherwise terminated, other than by exercise, shall be added back to the Shares available for issuance under the New 2021 Plan. The exercise price for grants made pursuant to the terms of the New 2021 Plan is determined in the applicable grant by the board of directors. Any incentive options granted to persons possessing less than 10% of the total combined voting power of all classes of stock may not have an exercise price of less than 100% of the fair market value of the common stock on the grant date. Any incentive options granted to persons possessing more than 10% of the total combined voting power of all classes of stock may not have an exercise price of less than 110% of the fair market value of the common stock on the grant date. The option term for incentive awards may not be greater than ten years from the date of the grant. Incentive options granted to persons possessing more than 10% of the total combined voting power of all classes of stock may not have an option term of greater than five years from the date of the grant. The vesting period for equity-based awards is determined at the discretion of the board of directors. As of December 31, 2021 there were options for 15,025,454 shares of Class A stock outstanding and options for 6,362,455 shares of Class B stock outstanding, of which 8,652,630 Class A and 4,786,936 Class B shares were exercisable, respectively. As of December 31, 2021, the maximum number of stock options awards available for future issuance under the Company’s plans is 7,209,538 . Stock Option Activity The following table summarizes stock option activity for the years ended December 31, 2021 and 2020: The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the common stock for those options that had exercise prices lower than the fair value of the common stock. The intrinsic value of options exercised during each of the years ended December 31, 2021 and 2020 were less than $ 0.1 million. The weighted-average grant-date fair value per share of options granted during the years ended December 31, 2021 and 2020 was $ 4.21 and $ 0.50 , respectively. The total fair value of options vested during the years ended December 31, 2021 and 2020 was $ 24.5 million and $ 0.8 million, respectively. Valuation of Stock Options Granted that Contain Service Conditions Only The fair value of each option award granted with service-based vesting is estimated on the date of the grant using the Black-Scholes option valuation model based on the assumptions noted in the table below for those options granted in the years ended December 31, 2021 and 2020: In August 2021, the Company canceled 378,786 existing Class A common stock options with service-based conditions held by Mei Mei Hu in exchange for an equal number of options to purchase shares of Class B common stock. The Company accounted for this exchange as a stock option modification. There was no incremental stock-based compensation expense as a result of this modification as the fair- value-based measures of the modified award immediately after the modification were less than the fair-value-based measures of the original award immediately before the modification. Stock Options Granted to Employees that Contain Performance and Market Conditions Included in the stock options granted during the year ended December 31, 2021 were stock options to purchase 6,799,625 shares of Class A common stock that contain performance- and market-based vesting conditions granted to the Mei Mei Hu, Louis Reese, and Peter Diamandis. In August 2021, the stock option awards for the Mei Mei Hu and Louis Reese totaling 5,983,670 shares were cancelled in exchange for an equal number of options to purchase shares of Class B common stock. The Company accounted for this exchange as a stock option modification. The fair value of the awards granted to Mei Mei Hu and Louis Reese at the modification date was $ 23.8 million, valued using the Monte-Carlo simulation model. The assumptions used in the Monte-Carlo simulation model were as follows: The stock option awards for Peter Diamandis totaling 815,955 shares had a grant date fair value of $ 0.3 million. The assumptions used in the Monte-Carlo simulation model were as follows: The compensation expense for these awards is recognized when the vesting condition is met for the performance-based criteria, and over the derived service period for the market-based criteria. The condition for the performance-based criteria in the stock options was based on the Company's completion of its IPO, and the condition for the market-based criteria in the stock options was based on the future price of the Company's common stock trading at or above a specified threshold. During the year ended December 31, 2021, stock options for an aggregate of 5,439,700 of the total 6,799,625 shares containing performance- and market-based vesting conditions were vested following the satisfaction of the performance-based condition achieved through the Company’s completion of its IPO. As of December 31, 2021, the market-based vesting conditions had not been achieved. Restricted Stock The following table summarizes the Company’s restricted stock activity for the year ended December 31, 2021: The aggregate fair value of restricted stock that vested was less than $ 0.1 million for the years ended December 31, 2021 and 2020. Stock-based compensation expense recognized on vested restricted stock was immaterial for the years ended December 31, 2021 and 2020. Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations (in thousands): As of December 31, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $ 26.8 million, which is expected to be recognized over a weighted average period of 3.3 years.

Other Long-Term Liabilities (Tables)	12 Months Ended
Other Long-Term Liabilities (Tables)	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Other Liabilities	December 31, 2021 2020 Accrued tax provision 236 236 Accrued rent 1 13 $ 237 $ 249

Net Loss Per Share (Tables)	12 Months Ended
Net Loss Per Share (Tables)	Dec. 31, 2021
Net Loss Per Share [Abstract]
Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share	December 31, 2021 2020 Series Seed preferred — 7,831,528 Series Seed-1 preferred — 22,876,457 Series Seed-2 preferred — 14,615,399 Series A-1 preferred — 1,871,511 Series A-2 preferred — 6,307,690 Unvested restricted stock — 23,970 Options and RSUs issued and outstanding 21,387,909 14,434,095 Warrants issued and outstanding stock 1,928,020 134,106 23,315,929 68,094,756

Equity Incentive Plan (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity Incentive Plan [Abstract]
Number of stock options, outstanding	9,276,399	7,610,289
Number of stock options, Granted	13,482,915	2,672,152
Number of stock options, Exercised	(186,204)	(283,290)
Number of stock options, Forfeited	(1,185,201)	(722,752)
Number of stock options, outstanding	21,387,909	9,276,399	7,610,289
Number of stock options, Exercisable	13,439,566
Weighted price per share, outstanding	$ 0.60	$ 0.33
Weighted price per share, Granted	8.20	1.17
Weighted price per share, Exercised	0.91	0.29
Weighted price per share, Forfeited	2.98	0.29
Weighted price per share, outstanding	5.25	$ 0.60	$ 0.33
Weighted price per share,exercisable	$ 4.40
Weighted contractual term, outstanding	7 years 4 months 24 days	7 years 7 months 6 days	8 years 7 months 6 days
Weighted contractual term, exercisable	6 years 9 months 18 days
Aggregate intrinsic value, outstanding	$ 49,684	$ 8,415	$ 2,357
Aggregate intrinsic value, exercisable	$ 37,969

Income Taxes (Schedule of Deferred Tax Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Net operating loss carryforwards	$ 32,405	$ 12,373
Compensation accruals	1,735	377
Other temporary differences	27	627
Gross deferred tax assets	34,167	13,377
Valuation allowance	(34,106)	(13,247)
Net deferred tax assets	61	130
Deferred Income Tax Liabilities	61	130
Deferred Tax Liabilities	$ 61	$ 130

Summary of Significant Accounting Policies (Restricted Cash) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Summary of Significant Accounting Policies [Abstract]
Cash and cash equivalents	$ 144,885	$ 31,143
Restricted cash	172	55
Total cash, cash equivalents and restricted cash	$ 145,057	$ 31,198	$ 476

Equity Incentive Plan (Schedule of Stock-Based Compensation Expense for Stock Options) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,014	$ 30,412
Research And Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	243	1,343
General And Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 771	$ 29,069

Fair Value Measurements (Schedule of Activity in Level 3, SAFE Arrangements) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in fair value	$ (8,365)	$ (615)
Level 3 [Member] \| SAFE Arrangements [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	24,335	0
Issuance of SAFEs	2,900	39,355
Change in fair value	8,365	615
Balance	0	24,335
Level 3 [Member] \| SAFE Arrangements [Member] \| Series Seed-2 Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Conversion to Series A-1 convertible preferred stock		360
Level 3 [Member] \| SAFE Arrangements [Member] \| Series A-2 Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Conversion to Series A-1 convertible preferred stock		$ 15,275
Level 3 [Member] \| SAFE Arrangements [Member] \| Series A Preferred Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Conversion to Series A-1 convertible preferred stock	$ 35,600

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2021
Income Taxes [Abstract]
Income Taxes	14. Income Taxes The sources of losses from continuing operations, before income taxes, classified between domestic entities and those entities domiciled outside of the U.S., are as follows (in thousands): Years Ended December 31, Losses before taxes 2021 2020 Domestic entities $ (128,538) $ (31,053) Entities outside the U.S. (8,636) (8,904) (137,175) $ (39,957) Years Ended December 31, 2021 2020 Current: Federal $ — $ — State and local — — Foreign — — Total current tax expense — — Deferred tax (benefit): Federal — — State and local — — Foreign — — Total deferred tax (benefit) — — Years Ended December 31, 2021 2020 Income taxes at statutory rate 21.00 % 21.00 % State income taxes, net of federal benefit 0.50 % 0.29 % Stock compensation (3.65) % 0.00 % Foreign rate differential (0.74) % (4.06) % Uncertain tax positions 0.00 % 0.00 % Other (1.90) % (0.36) % Change in valuation allowance (15.21) % (16.87) % Provision for income taxes 0.00 % 0.00 % As of December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 32,405 $ 12,373 Compensation accruals 1,735 377 Other 27 627 Total deferred tax assets 34,167 13,377 Less: valuation allowance (34,106) (13,247) Net deferred tax assets $ 61 $ 130 Deferred tax liabilities: Depreciation $ (61) $ (130) Net deferred tax liabilities (61) (130) Net deferred income taxes $ — $ — Years Ended December 31, 2021 2020 Uncertain tax position liability at the beginning of the year $ 652 $ 646 Increases (decreases) related to tax positions taken during current period — 6 Uncertain tax position liability at the end of the year $ 652 $ 652 Tax Expense (Benefit) The components of the provision for income taxes are as follows for the years ended December 31, 2021 and 2020 (in thousands): Tax Rate Reconciliation The Company’s effective tax rate for the years ended December 31, 2021 and 2020 was 0.00 % and 0.00 %, respectively. A reconciliation of the provision for income taxes at the statutory rate to the amount reflected in the consolidated statements of operations is as follows (in thousands): Deferred Tax Assets (Liabilities) The Company computes income taxes using the liability method. This method requires recognition of deferred tax assets and liabilities, measured by enacted rates, attributable to temporary differences between the financial statements and the income tax basis of assets and liabilities. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that certain deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those specific jurisdictions prior to the dates on which such net operating losses expire. The Company maintained a full valuation allowance against its net deferred tax assets for December 31, 2021 and 2020 because the Company has determined that it is more likely than not that these assets will not be fully realized based on a current evaluation of expected future taxable income and the Company is in a cumulative loss position. The valuation allowance increased by $ 6.7 million during the year ended December 31, 2020 and $ 20.9 million during the year ended December 31, 2021, primarily as a result of net operating losses generated during the periods. The Company reevaluates the positive and negative evidence at each reporting period. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): Net Operating Losses The Company had total net operating loss carryforwards for U.S. federal income tax purposes of $ 134.6 million, and $ 44.5 million as of December 31, 2021 and 2020, respectively, that have no expiration date. The Company has foreign net operating loss carryforwards of $ 24.0 million and $ 20.2 million, respectively, that have no expiration date. Utilization of the NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code Sections 382 and 383 (the “Code”), as amended, and similar state provisions. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company’s formation due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future. If the Company experienced an ownership change at any time since its formation, utilization of the NOL or tax credit carryforwards to offset future taxable income and taxes, respectively, would be subject to annual limitation under the Code. The annual limitation may result in the expiration of the NOL and credits before utilization. If impaired, the NOL and credit carryforwards would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. On March 27, 2020, the President of the United States signed into law the CARES Act, which, along with earlier issued IRS guidance, contains numerous provisions that may benefit the Company, including the deferral of certain taxes. There is no material impact to the Company. The CARES Act did not have a material impact on the Company’s tax provision for the year ended December 31, 2021. The Consolidated Appropriations Act, 2021, which was enacted on December 27, 2020, has expanded, extended, and clarified selected CARES Act provisions, specifically on Paycheck Protection Program loan and Employee Retention Tax Credit, 100% deductibility of business meals as well as other tax extenders. The Consolidated Appropriations Act did not have a material impact on the Company’s tax provision for the year ended December 31, 2021. The Company is subject to tax in the United States and many state and local jurisdictions. The Company, with certain exceptions, is subject to income tax examinations by U.S. federal, state and local for tax years 2017 and future periods. The company is not currently under audit for any US federal or state or foreign income tax audits. Uncertain Tax Positions A summary of the Company’s unrecognized tax benefits activity and related information is presented as follows (in thousands): The unrecognized tax benefits for U.S. jurisdiction of $ 0.6 million, if recognized, would not have an impact on the Company’s effective tax rate assuming the Company continues to maintain a full valuation allowance position against its U.S. deferred tax assets. The remaining unrecognized tax benefits of less than $ 0.1 million, if recognized, will have an impact on the effective tax rate. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. We accrued $ 0.2 million in interest and penalties related to prior year’s tax filings, as of December 31, 2021. The Company is subject to U.S. federal income tax as well as income tax of various foreign jurisdictions. Generally, the statute of limitations for examination of the Company’s U.S. federal and foreign income tax filings are open for the years ended December 31, 2017 and future periods.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Other Long-Term Liabilities (Other Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Accrued tax provision	$ 236	$ 236
Lease liability	13	1
Total	$ 249	$ 237

Net Loss Per Share	12 Months Ended
Net Loss Per Share	Dec. 31, 2021
Net Loss Per Share [Abstract]
Net Loss Per Share	15. Net Loss Per Share The Company’s unvested restricted common shares have been excluded from the computation of basic net loss per share. The Company’s potentially dilutive securities, which include options, unvested restricted stock, convertible notes payable and convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share as of December 31, 2021 and 2020 because including them would have had an anti-dilutive effect: December 31, 2021 2020 Series Seed preferred — 7,831,528 Series Seed-1 preferred — 22,876,457 Series Seed-2 preferred — 14,615,399 Series A-1 preferred — 1,871,511 Series A-2 preferred — 6,307,690 Unvested restricted stock — 23,970 Options and RSUs issued and outstanding 21,387,909 14,434,095 Warrants issued and outstanding stock 1,928,020 134,106 23,315,929 68,094,756

Fair Value Measurements (Narrative) (Details) - USD ($)	12 Months Ended
Fair Value Measurements (Narrative) (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2021
Class Of Warrant Or Right [Line Items]
Fair value asset transfers, level 1 to level 2		$ 0
Fair value asset transfers, level 2 to level 1		0
Fair value liability transfers, level 1 to level 2		0
Fair value liability transfers, level 2 to level 1		0
Fair value of preferred stock issued on conversion date	$ 15,600,000	$ 35,600,000
Series A-1 Preferred [Member]
Class Of Warrant Or Right [Line Items]
Number of shares available to purchase from vested warrants	71,862	205,970
Warrants, exercise price	$ 0.003	$ 0.003
Cash proceeds from warrants exercised	$ 1,000,000
Warrant outstanding	134,106

Convertible Notes Payable	12 Months Ended
Convertible Notes Payable	Dec. 31, 2021
Notes Payable [Abstract]
Convertible Notes Payable	8. Convertible Notes Payable Beginning in April 2018, the Company issued several Convertible Notes, some of which were issued to related parties. The Convertible Notes bear simple interest at annual rates ranging from 4.8 % to 6 %. All unpaid principal, together with the accrued interest thereon, are payable upon an event of default or upon maturity, which ranges from one to three years. The Convertible Notes contain a number of provisions addressing automatic and optional conversion, events of default, and prepayment provisions. The Company accounts for the Convertible Notes at fair value, in accordance with ASC 480, with any changes in fair value being recognized through the consolidated statements of operations. In accordance with the Contribution and Exchange Agreement, on March 2, 2021 each Reorganization Convertible Note that was outstanding was exchanged for shares of Series A preferred stock, as set forth in the applicable Convertible Note agreements and the Contribution and Exchange Agreement. During the years ended December 31, 2021 and 2020, the Company recognized interest expense of $ 0.2 million and $ 0.7 million, respectively, related to the Convertible Notes. In addition, in the years ended December 31, 2021 and 2020, the Company recognized a change in fair value of $ 2.7 million and $ 5.7 million in the accompanying consolidated statements of operations related to the Convertible Notes, respectively. The following table shows the activity of the Convertible Notes (in thousands): Convertible Notes Principal Amount Payable Change in Fair Value Accrued Interest Issuance Conversion to Standard Related Party Standard Related Party Standard Related Party Costs Series A Balance December 31, 2019 $ 11,170 $ 510 $ 33 $ 26 $ 378 $ 4 $ — $ — $ 12,121 Additions 2,040 10,000 1,884 3,822 560 179 (300) — 18,185 Settlements (5,500) — 55 — (264) — — — (5,709) Amortization — — — — — — 83 — 83 December 31, 2020 7,710 10,510 1,972 3,848 674 183 (217) — 24,680 Additions — 2,000 812 1,855 58 110 — — 4,835 Settlements (2,000) — — — (187) — — — (2,187) Amortization — — — — — — 217 — 217 Conversion of Convertible Notes to Series A preferred stock (5,710) (12,510) (2,784) (5,703) (545) (293) — (27,545) (27,545) December 31, 2021 $ — $ — $ — $ — $ — $ — $ — $ (27,545) $ —

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Nature of the Business (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($)
Nature of Business Disclosures [Line Items]
Proceeds from issuance of convertible notes payable with related parties \| $	$ 2,000	$ 12,040
Repayment of convertible notes \| $	$ 2,000	5,500
Note conversion ratio	3.4233
Issuance of stock, shares	32,505,306
Cash and cash equivalents \| $	$ 144,885	31,143
Net Income Loss \| $	(137,175)	(39,957)
Accumulated deficit \| $	$ (229,481)	$ (92,306)
Reverse stock split	1.556
ConvertiblePreferredStockSharesIssuedUponConversion	3.4233
Debt Conversion Converted Instrument Shares Issued 1	4,047,344
Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares	6,000,000
Share Price \| $ / shares	$ 13.00
Underwriters [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares	900,000
Underwriters [Member] \| Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares	537,711
Share Price \| $ / shares	$ 71.1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2021
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	December 31, 2021 2020 Deposits $ 4,379 $ 10 Prepaid materials and supplies 4,131 3,302 Other 341 832 $ 8,851 $ 4,144

Notes payable (Carrying Value) (Details) - Note, 2025 [Member] - Notes Payable [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Principal	$ 10,883	$ 11,298
Unamortized debt issuance cost	184	237
Total	10,699	11,061
Less: current portion	(376)	(362)
Note payable, net of current portion and debt issuance cost	$ 10,323	$ 10,699

- Definition

Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References + Details

Common Stock (Tables)	12 Months Ended
Common Stock (Tables)	Dec. 31, 2021
Common Stock [Abstract]
Reserved Shares of Common Stock for Issuance	December 31, 2021 2020 Series Seed preferred — 7,831,528 Series Seed-1 preferred — 22,876,457 Series Seed-2 preferred — 14,615,399 Series A-1 preferred — 1,871,511 Series A-2 preferred — 6,307,690 Options issued and outstanding 21,387,909 9,276,399 Options available for future grants 7,209,538 1,897,049 Warrants issued and outstanding 1,928,020 86,186 30,525,467 64,762,219

Simple Agreement for Future Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Aug. 31, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity			$ 0	$ 24,335
Shares issued			32,505,306
Loss on fair value of investment			$ (8,365)	(615)
SAFE 1 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity		$ 400
SAFE 2 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity	$ 14,700
Shares issued	6,307,690
Share Price	$ 2.3241
SAFE 3 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity			2,900	$ 24,300
Minimum value of qualified financing, equity financing provision			$ 50,000
Series Seed-2 Stock [Member] \| SAFE 1 [Member]
Simple Agreement for Future Equity [Line Items]
Shares issued		463,162
Share Price		$ 0.7773

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2021
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2021 2020 Deposits $ 4,379 $ 10 Prepaid materials and supplies 4,131 3,302 Other 341 832 $ 8,851 $ 4,144 The Company’s prepaid material and supplies related to ELISA test production, of which $ 1.0 million was paid to a related party and $ 2.5 million related to materials to be utilized during its Phase 2 clinical trial for COVID-19 vaccine development.

Equity Incentive Plan (Weighted Average Assumptions) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.59%	0.34%
Risk-free interest rate, maximum	1.35%	0.38%
Expected volatility, minimum	71.60%	70.90%
Expected volatility, maximum	93.40%	86.84%
Mei Mei Hu and Louis Reese [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	58.00%
Expected term (in years)	4 years 6 months
Expected volatility	75.00%
Cost Of Equity	25.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	$ 10.07
Peter Diamandis [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.09%
Expected term (in years)	1 year
Expected volatility	90.00%
Cost Of Equity	25.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	$ 4.12
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 3 months 18 days	6 years 29 days
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	5 years	5 years 7 months 6 days

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
Accrued Expenses and Other Current Liabilities (Tables)	Dec. 31, 2021
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued expenses and other current liabilities	December 31, 2021 2020 Accrued bonuses $ 2,294 $ 2,187 Accrued external research and development 1,501 296 Accrued professional fees and other 692 228 Accrued interest 32 33 $ 4,519 $ 2,744

Fair Value Measurements (Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	$ 139,794	$ 10,356
Simple agreement for future equity	0	24,335
Warrant liability	0	400
Liabilities	139,794	49,415
Cash and cash equivalents	144,885	31,143
Convertible Notes Payable, Related Party, Fair Value		14,324
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	139,794
Liabilities	139,794
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable		10,356
Simple agreement for future equity		24,335
Warrant liability		400
Liabilities	$ 0	49,415
Convertible Notes Payable, Related Party, Fair Value		$ 14,324

Prepaid Expenses and Other Current Assets (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid materials and supplies	$ 10	$ 4,379
Deposits	3,302	4,131
Other	832	341
Total	$ 4,144	$ 8,851

Convertible Notes Payable (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Proceeds from issuance of convertible notes payable with related parties	$ 2,000	$ 12,040
Convertible Debt [Member]
Debt Instrument [Line Items]
Interest Expense, Debt	200	700
Change in fair value	$ 2,700	$ 5,700
Convertible Debt [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Stated Percentage	4.80%
Convertible Debt [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Stated Percentage	6.00%

Related Party Transactions (Schedule of Related Party Operating Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Prepaid expenses and other current assets	$ 4,144	$ 8,851
Property and equipment, net	12,173	12,158
Revenue	66	557
Cost of revenue	1,937	52
Due From Related Parties	400	400
Due to related parties	19,400	8,000
UBI IP [Member] \| Services Provided By Related Parties [Member]
Related Party Transaction [Line Items]
Prepaid expenses and other current assets	3,517	2,867
Property and equipment, net	337	725
Accrued expenses	0	285
Revenue	0	162
Cost of revenue	0	52
Reimbursement from related party	17,987	41,430
General and administrative	3,147	1,173
Due From Related Parties	393	361
Due to related parties	19,407	8,004
UBI IP [Member] \| Taiwan CDC Grant [Member]
Related Party Transaction [Line Items]
Reimbursement from related party	$ (2,948)	$ (7,199)

Notes payable (Annual Principal Payments) (Details) - Note, 2025 [Member] - Notes Payable [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
2021	$ 429
2022	444
2023	458
2024	9,552
Total	$ 10,883	$ 11,298

Convertible Notes Payable (Convertible Notes) (Details) - Convertible Debt [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 24,680	$ 12,121
Additions	4,835	18,185
Settlements	(2,187)	(5,709)
Amortization	217	83
Conversion of Convertible Notes to Series A preferred stock	(27,545)
Balance	0	24,680
Issuance Costs [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	(217)	0
Additions	0	(300)
Settlements	0	0
Amortization	217	83
Conversion of Convertible Notes to Series A preferred stock	0
Balance	0	(217)
Conversion to Series A Preferred [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	0	0
Additions	0	0
Settlements	0	0
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(27,545)
Balance	(27,545)	0
Principal Amount [Member] \| Standard [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	7,710	11,170
Additions	0	2,040
Settlements	(2,000)	(5,500)
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(5,710)
Balance	0	7,710
Principal Amount [Member] \| Related Party [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	10,510	510
Additions	2,000	10,000
Settlements	0	0
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(12,510)
Balance	0	10,510
Change In Fair Value [Member] \| Standard [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	1,972	33
Additions	812	1,884
Settlements	0	55
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(2,784)
Balance	0	1,972
Change In Fair Value [Member] \| Related Party [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	3,848	26
Additions	1,855	3,822
Settlements	0	0
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(5,703)
Balance	0	3,848
Accrued Interest [Member] \| Standard [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	674	378
Additions	58	560
Settlements	(187)	(264)
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(545)
Balance	0	674
Accrued Interest [Member] \| Related Party [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	183	4
Additions	110	179
Settlements	0	0
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(293)
Balance	$ 0	$ 183

Nature of the Business	12 Months Ended
Nature of the Business	Dec. 31, 2021
Nature of the Business [Abstract]
Nature of the Business	1. Nature of the Business Vaxxinity, Inc., a Delaware corporation (“Vaxxinity ,” and together with its subsidiaries, the “Company”), was formed through the combination of two separate businesses that originated from United Biomedical, Inc. (“UBI”) in two separate transactions: a spin-out from UBI in 2014 of operations focused on developing chronic disease product candidates that resulted in United Neuroscience (“UNS”), and a second spin-out from UBI in 2020 of operations focused on the development of a COVID-19 vaccine that resulted in C19 Corp. (“COVAXX”). On February 2, 2021, Vaxxinity was incorporated for the purpose of reorganizing and combining UNS and COVAXX and on March 2, 2021, did so by acquiring all of the outstanding equity interests of UNS and COVAXX pursuant to a contribution and exchange agreement (the “Contribution and Exchange Agreement”) whereby the existing equity holders of UNS and COVAXX contributed their equity interests in each of UNS and COVAXX in exchange for equity in Vaxxinity (the “Reorganization”). The Company is a biotechnology company currently focused on developing product candidates for human use in the fields of neurology and coronaviruses utilizing its “Vaxxine Platform”—a peptide vaccine technology first developed by UBI and subsequently refined over the last two decades. The Company is engaged in the development and commercialization of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical need. UBI is a significant shareholder of the Company and, therefore, considered a related party. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability. The Company’s product candidates are in development and will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and is dependent upon the services of its employees and consultants. Contribution and Exchange Agreement On March 2, 2021, in accordance with the Contribution and Exchange Agreement, (i) all outstanding shares of UNS and COVAXX preferred stock and common stock were contributed to Vaxxinity and exchanged for like shares of stock in Vaxxinity, (ii) the outstanding options to purchase shares of UNS and COVAXX common stock were terminated and substituted with options to purchase shares of common stock in Vaxxinity, (iii) the outstanding warrant to purchase shares of COVAXX common stock was cancelled and exchanged for a warrant to acquire common stock in Vaxxinity and (iv) each outstanding Reorganization Convertible Note (as defined below) was contributed to Vaxxinity and the holders of such notes received Series A preferred stock in Vaxxinity. In particular: • Each UNS common share and convertible preferred share was exchanged for 0.2191 shares of Vaxxinity common stock or Series A preferred stock, as applicable; • Each share of COVAXX common and convertible preferred stock was exchanged for 3.4233 shares of Vaxxinity common stock or Series A preferred stock, as applicable (and prior to the closing of the Reorganization, all the holders of outstanding COVAXX SAFEs agreed to convert such SAFEs into shares of Series A-3 preferred stock of COVAXX, which shares were then exchanged for shares of Vaxxinity’s Series A preferred stock); • The Reorganization Convertible Notes were exchanged for an aggregate of 4,047,344 shares of Vaxxinity’s Series A preferred stock; and • Each outstanding option of both UNS and COVAXX to purchase common shares of UNS or COVAXX was terminated and substituted with an option to purchase shares of Class A common stock of Vaxxinity. Each outstanding UNS option was exchanged based on a conversion ratio of 0.2191 . Each outstanding COVAXX option was exchanged based on a conversion ratio of 3.4233 . All parties to the Contribution and Exchange Agreement intend that the contribution of outstanding equity interests to Vaxxinity in exchange for Vaxxinity’s common stock and preferred stock will be treated as an integrated transaction for U.S. federal income tax purposes that is governed by Section 351(a) of the Internal Revenue Code of 1986, as amended. The Reorganization was determined to be a common control transaction, so the carrying values of all contributed assets and assumed liabilities remained unchanged and the financial information for all periods in the financial statements presented prior to the Reorganization are presented on a consolidated basis. Reverse Stock Split On October 29, 2021, the Company effectuated a reverse stock split of 1-for- 1.556 (the “Stock Split”) of the Company’s Class A and Class B common stock pursuant to an amendment to the Company’s Amended and Restated Certificate of Incorporation approved by the Company’s board of directors and stockholders. As a result of the Stock Split, the Company also adjusted the share and per share amounts associated with its options and warrants to purchase shares of its common stock. These consolidated financial statements including the notes have been retroactively adjusted to reflect the Stock Split for all periods presented. Any fractional shares that would have resulted from the Stock Split have been rounded down to the nearest whole share. Initial Public Offering On November 15, 2021, the Company closed its IPO of 6,000,000 shares of Class A common stock at a public offering price of $ 13.00 per share. On November 18, 2021 the Company held a subsequent closing for the issuance of an additional 537,711 shares of Class A common stock pursuant to a 30-day option granted to the underwriters to purchase up to an additional 900,000 shares of Class A common stock at the IPO price, less underwriting discounts and commissions. The aggregate net proceeds to the Company from the offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, was approximately $ 71.1 million. Upon the closing of the IPO, all previously outstanding shares of the Company’s redeemable convertible preferred stock were automatically converted at the same ratio used for the Stock Split (1-for- 1.556 ) into shares of its Class A common stock. Liquidity As of December 31, 2021, the Company had $144.9 million of cash and cash equivalents. To date, the Company has primarily financed its operations through the sale of convertible preferred stock and common stock and borrowings under promissory notes (including Convertible Notes), a portion of which has been raised from related party entities. The Company has experienced significant negative cash flows from operations since inception, and incurred a net loss of $137.2 million for the year ended December 31, 2021. Net cash used in operating activities for the year ended December 31, 2021 was $81.0 million. In addition, as of December 31, 2021, the Company has an accumulated deficit of $229.5 million. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. As of the date these financial statements were available to be issued, the Company expects its existing cash and cash equivalents to be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months. The Company will need to obtain additional funding beyond the period that is 12 months from the date these financial statements were available to be issued whether through collaboration agreements, private or public equity or debt offerings or a combination thereof, and such additional funding may not be available on terms the Company finds acceptable or at all. If the Company is unable to obtain sufficient capital to continue to advance its programs, the Company would be forced to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that the Company would otherwise prefer to develop and market itself. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Impact of COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of a COVID-19 pandemic. The COVID-19 pandemic is evolving, and to date, has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its operations and the operations of its customers, suppliers, vendors and business partners. The Company does not yet know the full extent of potential delays or impacts on its business, its clinical trials, its research programs, healthcare systems or the global economy and it cannot presently predict the scope and severity of any potential business shutdowns or disruptions. The extent to which COVID-19 impacts its business, results of operation and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions to contain COVID-19 or treat its impact, among others. If the Company or any of the third parties with whom the Company engages, however, were to experience shutdowns or other business disruptions, its ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on its business, results of operation and financial condition. The Company has not incurred impairment losses in the carrying values of its assets as a result of the COVID-19 pandemic and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these consolidated financial statements.

Common Stock (Reserved Share of Common Stock for Issuance) (Details) - shares	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Options issued and outstanding	21,387,909	9,276,399	7,610,289
Options [Member]
Class Of Stock [Line Items]
Options issued and outstanding		9,276,399
Options available for future grants		1,897,049
Warrants issued and outstanding to purchase shares of common stock		86,186
Reserved Shares of Common Stock		64,762,219
Series seed-1 convertible preferred shares [Member] \| Options [Member]
Class Of Stock [Line Items]
Preferred stock		22,876,457
Series seed-2 convertible preferred shares [Member] \| Options [Member]
Class Of Stock [Line Items]
Preferred stock		14,615,399
Series Seed Stock [Member]
Class Of Stock [Line Items]
Preferred stock	0	10,452
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock	0	0
Series A-1 Preferred [Member] \| Options [Member]
Class Of Stock [Line Items]
Preferred stock		1,871,511
Series A-2 preferred [Member] \| Options [Member]
Class Of Stock [Line Items]
Preferred stock		6,307,690
Series Seed Preferred [Member] \| Options [Member]
Class Of Stock [Line Items]
Preferred stock		7,831,528
Options issued and outstanding	21,387,909
Options available for future grants	7,209,538
Warrants issued and outstanding to purchase shares of common stock	1,928,020
Reserved Shares of Common Stock	30,525,467

Related Party Transactions (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Due to related parties	$ 19,400	$ 8,000
Service fees	35,400	18,200
Prepaid expenses	4,144	8,851
Due From Related Parties	$ 400	$ 400
UBI [Member]
Related Party Transaction [Line Items]
Percent of ownership	43.00%

- Definition

For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10(3))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.3)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

+ Details

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

- Definition

Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

+ Details

Notes Payable	12 Months Ended
Notes Payable	Dec. 31, 2021
Notes payable with related parties [Abstract]
Notes payable with related parties [Text Block]	9. Notes Payable Notes Payable with Related Parties In December 2018, the Company entered into related party convertible notes payable (the “2018 Related Notes” and together with the Convertible Notes, the “Reorganization Convertible Notes”) for $ 2.0 million in aggregate proceeds, received in three tranches. The 2018 Related Notes bore simple interest at an annual rate of 5 % and contain a number of provisions addressing events of default and prepayment. In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the 2018 Related Notes were converted into Series A preferred stock. During the years ended December 31, 2021 and 2020, the Company recognized interest expense of less than $ 0.1 million on the 2018 Related Notes. 2019 Executive Note In November 2019, the Company borrowed $ 0.1 million from its Chief Executive Officer (the “2019 Executive Note”). No formal loan agreement was executed. However, the Company has elected to accrue interest at an annual rate of 5 %, consistent with the terms and conditions of the Convertible Notes and 2018 Related Notes, which was the closest benchmark the Company could evaluate. The 2019 Executive Note was repaid in August 2021. The activity of the 2018 Related Notes and 2019 Executive Note is as follows (in thousands): Note Payable—Airplane In connection with the acquisition of an airplane, the Company entered into a note payable agreement (the “2025 Note”) in June 2020 for $ 11.5 million, with an annual interest rate of 3.4 % and a maturity date of June 9, 2025. Principal and interest payments are payable monthly in the amount of $ 0.07 million with a final payment of $ 9.4 million at maturity. The 2025 Note is guaranteed by the co-founders of the Company. In addition, the Company incurred debt issuance costs of $ 0.3 million, which are being amortized over the term of the loan. There are no financial covenants associated with the 2025 Note. The carrying value of the 2025 Note is as follows (in thousands): As of December 31, 2021, the remaining principal payments for the 2025 Note, are as follows (in thousands): Interest expense associated with the 2025 Note was $ 0.4 million and $ 0.2 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, accrued interest of less than $ 0.1 million was included in accrued expenses and other liabilities in the accompanying consolidated balance sheets. Note Payable—Paycheck Protection Program The Company applied for and received a loan, which is in the form of a note dated May 5, 2020, from HSBC Bank USA, National Association (“HSBC”) in the aggregate amount of approximately $ 0.3 million (the “PPP Loan”), pursuant to the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. As of December 31, 2021, there were no events of default under the PPP Loan. The Company paid off the PPP Loan in full, including all accrued but unpaid interest to the repayment date, in August 2021. 2018 Related Notes and 2019 Executive Note Related Party Principal Accrued Interest Balance December 31, 2019 $ 2,100 $ 88 $ 2,188 Additions — 106 106 December 31, 2020 2,100 194 2,294 Accrued interest — 19 19 Repayment (100) — (100) Interest paid — (8) (8) Conversion (2,000) (205) (2,205) December 31, 2021 $ — $ — $ —